Document:

EX-10.1

 Exhibit 10.1 
 EXECUTION VERSION 
 SUPPORT AGREEMENT 

This SUPPORT AGREEMENT dated as of May 23, 2013 (this “Agreement”), is by and among the stockholders listed on the
signature page(s) hereto (collectively, the “Stockholders” and each individually, a “Stockholder”), rue21, inc., a Delaware corporation (the “Company”) and, solely for purposes of Sections 1(a)
hereof, and, to the extent applicable, Section 9 hereof, Rhodes Holdco, Inc., a Delaware corporation (“Parent”). Capitalized terms used and not otherwise defined herein shall have the respective meanings ascribed to them in the
Merger Agreement (as defined below). 
 RECITALS 
 WHEREAS, as of the date hereof, the Stockholders beneficially own an aggregate of 7,091,918 shares of common stock of the Company, as set forth on Schedule I hereto (such shares, or any other voting or
equity securities of the Company hereafter acquired by any Stockholder prior to the termination of this Agreement, being referred to herein collectively as the “Subject Shares”); 

WHEREAS, concurrently with the execution of this Agreement, Parent, Rhodes Merger Sub, Inc., a newly formed Delaware corporation and
wholly owned subsidiary of Parent (“Merger Sub”), and the Company are entering into an Agreement and Plan of Merger, dated as of the date hereof, and as may be modified or amended from time to time (the “Merger
Agreement”), pursuant to which, upon the terms and subject to the conditions thereof, Merger Sub will be merged with and into the Company, with the Company surviving the Merger as a wholly owned Subsidiary of Parent (the
“Merger”); and 
 WHEREAS, as a condition to the willingness of the Company to enter into the Merger Agreement,
the Company has required that the Stockholders agree, and in order to induce the Company to enter into the Merger Agreement, the Stockholders are willing, to enter into this Agreement. 

NOW, THEREFORE, in consideration of the foregoing and the mutual covenants and agreements contained herein, and intending to be legally
bound hereby, the parties hereby agree as follows: 
 SECTION 1. Voting of Subject Shares. From the period
commencing with the execution and delivery of this Agreement and continuing until the Expiration Date, at every meeting of the stockholders of the Company called with respect to any of the following, and at every adjournment or postponement thereof,
and on every action or approval by written consent of the stockholders of the Company with respect to any of the following, each Stockholder shall vote or cause to be voted the Subject Shares: 

(a) (i) in favor of the adoption of the Merger Agreement and the approval of the transactions contemplated thereby, including
the Merger, and any actions required in furtherance thereof, (ii) in favor of any proposal to adjourn or postpone such stockholders meeting to a later date if there are not sufficient votes to approve and adopt the Merger Agreement, and
(iii) against any other action or agreement that is not recommended by the Board of Directors of the Company (acting upon the recommendation of Special Committee) and that would reasonably be

 
expected to (A) result in a breach of any covenant, representation or warranty or any other obligation or agreement of the Company under the Merger Agreement, (B) result in any of the
conditions to the consummation of the Merger under the Merger Agreement not being fulfilled, or (C) impede, frustrate, interfere with, delay, postpone or adversely affect the Merger and the other transactions contemplated by the Merger
Agreement (it being agreed that this clause (a) may be enforced by Parent); and 
 (b) in the event that the Merger
Agreement is terminated in accordance with Section 8.3(a) thereof in order to concurrently enter into an Alternative Acquisition Agreement that constitutes a Superior Proposal which provides for cash consideration of no less than $42.00
per share, in favor of the adoption of such Alternative Acquisition Agreement and the approval of the transactions contemplated thereby if recommended to the stockholders by the Board of Directors of the Company (acting upon the recommendation of
the Special Committee) in the same proportion as the number of Shares owned by Unaffiliated Stockholders (as defined below) that are voted in favor of the adoption of such Alternative Acquisition Agreement and the approval of the transactions
contemplated thereby bears to the total number of Shares voted by Unaffiliated Stockholders and, in favor of any other matter with respect to such Alternative Acquisition Agreement and the approval of the transactions contemplated thereby that is
submitted for a vote of the stockholders of the Company, if recommended by the Board of Directors of the Company (acting upon the recommendation of the Special Committee), in the same proportion as the number of Shares owned by Unaffiliated
Stockholders that are voted in favor of such matter bears to the total number of Shares voted by Unaffiliated Stockholders; provided that, in each case, in lieu of voting in such proportion, each Stockholder may, in his or its sole
discretion, vote or cause to be voted all (or an amount between such proportion and all) of the Subject Shares that such Stockholder is entitled to vote in favor of any matter referred to in this Section 1(b). 

(c) “Unaffiliated Stockholders” means holders of Shares other than Parent, Merger Sub, the Stockholders (or their Permitted
Transferees), any Specified Party or any other Person having any equity interest in, or any right to acquire any equity interest in, Merger Sub or any Person of which Merger Sub is a direct or indirect Subsidiary. The Company shall timely provide to
each Stockholder reasonably sufficient information to confirm the manner in which the Shares shall be, or have been, voted at any stockholder meeting pursuant to Sections 1(a) and (b); and the Stockholders obligations thereunder shall
be contingent upon the timely provision of such information by the Company to the Stockholders. For the avoidance of doubt, each Stockholder shall be deemed to have fulfilled its obligations in full under Section 1(b) and
Section 2 with respect to any votes or acceptances of offers required of the Stockholder thereunder in the event that the proportion of Subject Shares voted, tendered or exchanged by the Stockholder, as applicable, corresponds to (or
exceeds) the proportion indicated by the information made available by the Company to the Stockholder prior to the applicable voting or tender period expiring. 
 SECTION 2. Tendering of Shares. 
 In the event that the Merger
Agreement is terminated in accordance with Section 8.3(a) thereof in order to concurrently enter into an Alternative Acquisition Agreement that constitutes a Superior Proposal that is structured as a tender offer and which provides for
cash 

  
 2 

 
consideration of no less than $42.00 per share, the Stockholders shall (i) accept such offer in the same proportion as the number of Shares owned by Unaffiliated Stockholders that are
tendered or exchanged bears to the total number of Shares owned by Unaffiliated Stockholders and tender or exchange, as applicable, such proportion of the Subject Shares pursuant to such offer, provided that in lieu of tendering in such proportion,
each Stockholder may, in his or its sole discretion, tender or exchange or cause to be tendered or exchanged all or a greater proportion of its Subject Shares, and (ii) not withdraw any Subject Shares tendered pursuant to such offer (unless
recommended to do so by the Board of Directors of the Company (acting upon the recommendation of the Special Committee) in which case it may so withdraw such Subject Shares). The Company shall timely provide to each Stockholder sufficient
information to confirm the manner in which the Shares shall be, or have been, tendered in any tender or exchange offer pursuant to this Section 2; and the Stockholders obligations under this Section 2 shall be contingent upon
the timely provision of such information by the Company to the Stockholders. 
 SECTION 3. Transfer of Shares.

 Except as specifically contemplated by this Agreement, each Stockholder covenants and agrees that such Stockholder will
not directly or indirectly (a) sell, assign, transfer, tender, pledge, encumber or otherwise dispose of or consent to any of the foregoing (each, a “Transfer”), or cause to be Transferred, any of the Subject Shares,
(b) deposit any of the Subject Shares into a voting trust or enter into a voting agreement or arrangement with respect to the Subject Shares or grant any proxy or power of attorney with respect thereto that is inconsistent with this Agreement
or (c) enter into any contract, option or other arrangement or undertaking with respect to any Transfer of any Subject Shares; provided, that, notwithstanding anything to the contrary set forth herein, any Stockholder may Transfer
Subject Shares to any other Stockholder or to a controlled Affiliate of any other Stockholder so long as such controlled Affiliate (a “Permitted Transferee”) agrees to be bound by the terms of this Agreement as a Stockholder with
respect to such Subject Shares. Nothing herein shall restrict or otherwise limit the encumbrance or pledge of Subject Shares pursuant to margin and/or other pledge arrangements, provided that with respect to any margin or pledge arrangement, the
voting rights of the relevant Subject Shares shall be subject to Section 1 hereof. 
 SECTION 4.
Acquisition Proposals. 
 (a) If any Stockholder receives any inquiry or proposal that constitutes an Acquisition
Proposal, such Stockholder shall promptly inform the Company of such inquiry or proposal and the details thereof. 
 (b) Each
Stockholder shall keep confidential from Apax Partners, L.P. and its Affiliates (excluding, for the avoidance of doubt, the SKM Funds, Saunders Karp & Megrue Partners, LLC and Persons controlled by Saunders Karp & Megrue Partners,
LLC) (collectively “Apax”) the specific terms and conditions of any Acquisition Proposal made by a Person other than Apax or by a group of Persons of which Apax is not a member. 

  
 3 

 SECTION 5. Additional Covenants of the Stockholders. 

(a) Waiver of Appraisal Rights. Each Stockholder hereby waives, to the fullest extent permitted by Law, and agrees not to assert
any appraisal rights pursuant to Section 262 of the DGCL or otherwise, with respect to any and all Subject Shares held by the Stockholders of record or beneficially owned, in connection with (i) the Merger (unless the Board of Directors of
the Company (upon the recommendation of the Special Committee) has effected a Company Adverse Recommendation Change that has not been rescinded or withdrawn), or (ii) any merger in connection with an Alternative Acquisition Agreement that
constitutes a Superior Proposal and which provides for cash consideration of no less than $42.00 per share (unless the Board of Directors of the Company (acting upon the recommendation of the Special Committee) has recommended against the adoption
of such Alternative Acquisition Agreement or the transactions contemplated thereby and such recommendation has not been rescinded or withdrawn). 
 SECTION 6. Representations and Warranties of the Stockholders. 

Each Stockholder, severally and not jointly and severally, and solely as to itself, represents and warrants to the Company with respect
to such Stockholder and such Stockholder’s ownership of the Subject Shares as follows: 
 (a) Number of Shares. Such
Stockholder represents, warrants and agrees that Schedule I annexed hereto sets forth, adjacent to the name of such Stockholder, the number of Subject Shares of which such Stockholder is the beneficial owner (it being understood and agreed that the
beneficial ownership shall not include any rights with respect to derivatives, swaps or other arrangements) and that such Stockholder has continuously owned such Shares for at least three years prior to the date hereof. Such Stockholder represents,
warrants and agrees that, as of the date hereof, those Subject Shares on Schedule I constitute all of the Subject Shares of which such Stockholder has the power to vote or direct the vote. 

(b) Power, Binding Agreement. Such Stockholder is a limited partnership or general partnership, as applicable, duly formed, under
the Laws of its state of formation and has full limited partnership or general partnership, as applicable, power and authority to execute and deliver this Agreement and to consummate the transactions contemplated hereby. The execution and delivery
of this Agreement by such Stockholder and the consummation of the transactions contemplated hereby have been duly and validly authorized by the appropriate governing body of such Stockholder, and, no other limited partnership or general partnership,
as applicable, proceedings on the part of such Stockholder are necessary to authorize the execution, delivery and performance of this Agreement by such Stockholder and the consummation of the transactions contemplated hereby. Such Stockholder has
duly and validly executed this Agreement, and this Agreement constitutes a legal, valid and binding obligation of such Stockholder, enforceable against such Stockholder in accordance with its terms, except as such enforceability may be limited by
applicable bankruptcy, insolvency, reorganization or other similar Laws affecting creditors’ rights generally and by general equitable principles (regardless of whether enforceability is considered in a proceeding in equity or at Law).

 (c) Reliance by the Company. Such Stockholder understands and acknowledges that the Company is entering into the
Merger Agreement in reliance upon such Stockholder’s execution and delivery of this Agreement. 
 (d) Litigation. As
of the date hereof, to the knowledge of such Stockholder, there is no action, proceeding or investigation pending or threatened against such Stockholder that questions the validity of this Agreement or any action taken or to be taken by such
Stockholder in connection with this Agreement. 

  
 4 

 SECTION 7. Representations and Warranties of the Company. 

 The Company represents and warrants to the Stockholders as follows: 

(a) Power, Binding Agreement. The Company is a corporation duly incorporated, validly existing and in good standing under the Laws
of the State of Delaware and has full corporate power and authority to execute and deliver this Agreement and to consummate the transactions contemplated hereby. The execution and delivery of this Agreement by the Company and the consummation of the
transactions contemplated hereby have been duly and validly authorized by the Board of Directors of the Company (acting upon the recommendation of the Special Committee), and no other corporate proceedings on the part of the Company are necessary to
authorize the execution, delivery and performance of this Agreement by the Company and the consummation of the transactions contemplated hereby. The Company has duly and validly executed this Agreement and this Agreement constitutes a legal, valid
and binding obligation of the Company enforceable against the Company in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization or other similar Laws affecting creditors’
rights generally and by general equitable principles (regardless of whether enforceability is considered in a proceeding in equity or at Law). 
 SECTION 8. Termination.  
 This Agreement shall
automatically terminate without further action upon the earliest to occur (the “Expiration Date”) of (a) the Effective Time, (b) the termination of the Merger Agreement in accordance with its terms, except in the event
that the Merger Agreement is terminated pursuant to Section 8.3(a) thereof and the Company concurrently enters into an Alternative Acquisition Agreement that constitutes a Superior Proposal that provides for cash consideration of no less
than $42.00 per share, and (c) in the event that the Merger Agreement is terminated pursuant to Section 8.3(a) thereof and the Company concurrently enters into an Alternative Acquisition Agreement that constitutes a Superior
Proposal that provides for cash consideration of no less than $42.00 per share, upon the earlier of (A) the effective time or consummation of any merger of the Company provided for in connection with such Alternative Acquisition Agreement, or
if there is no provision for such a merger, the closing of the transactions contemplated thereby and (B) the termination of such Alternative Acquisition Agreement in accordance with its terms. 

SECTION 9. Miscellaneous.  
 (a) Entire Agreement. This Agreement constitutes the entire agreement and supersedes all other prior agreements, understandings, representations and warranties both written and oral, among the
parties, with respect to the subject matter hereof. 

  
 5 

 (b) Modification or Amendment. The parties hereto may only modify or amend this
Agreement by written agreement of each of the parties hereto. 
 (c) Severability. The provisions of this Agreement shall
be deemed severable and the invalidity or unenforceability of any provision shall not affect the validity or enforceability of the other provisions hereof. If any provision of this Agreement, or the application thereof to any Person or circumstance,
is invalid or unenforceable, (a) a suitable and equitable provision shall be substituted therefor in order to carry out, so far as may be valid and enforceable, the intent and purpose of such invalid or unenforceable provision and (b) the
remainder of this Agreement and the application of such provision to other Persons or circumstances shall not be affected by such invalidity or unenforceability, nor shall such invalidity or unenforceability affect the validity or enforceability of
such provision, or the application thereof, in any other jurisdiction. 
 (d) Governing Law and Venue; Waiver of Jury Trial;
Specific Performance. 
 (i) THIS AGREEMENT SHALL BE DEEMED TO BE MADE IN AND IN ALL RESPECTS SHALL BE INTERPRETED,
CONSTRUED AND GOVERNED BY AND IN ACCORDANCE WITH THE LAW OF THE STATE OF DELAWARE WITHOUT REGARD TO THE CONFLICTS OF LAW PRINCIPLES THEREOF TO THE EXTENT THAT SUCH PRINCIPLES WOULD DIRECT A MATTER TO ANOTHER JURISDICTION. The parties hereby
irrevocably submit to the personal jurisdiction of the Court of Chancery of the State of Delaware, or to the extent such court does not have subject matter jurisdiction, the United States District Court for the District of Delaware (the
“Chosen Courts”) solely in respect of the interpretation and enforcement of the provisions of this Agreement and of the documents referred to in this Agreement, and in respect of the transactions contemplated hereby, and hereby
waive, and agree not to assert, as a defense in any action, suit or proceeding for the interpretation or enforcement hereof or of any such document, that it is not subject thereto or that such action, suit or proceeding may not be brought or is not
maintainable in the Chosen Courts or that the Chosen Courts are an inconvenient forum or that the venue thereof may not be appropriate, or that this Agreement or any such document may not be enforced in or by such Chosen Courts, and the parties
hereto irrevocably agree that all claims relating to such action, suit or proceeding shall be heard and determined in the Chosen Courts. The parties hereby consent to and grant any such Chosen Court jurisdiction over the person of such parties and,
to the extent permitted by Law, over the subject matter of such dispute and agree that mailing of process or other papers in connection with any such action, suit or proceeding in the manner provided in Section 9(f) or in such other
manner as may be permitted by Law shall be valid, effective and sufficient service thereof. 
 (ii) EACH OF THE COMPANY AND EACH
STOCKHOLDER ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH SUCH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT SUCH PARTY MAY
HAVE TO A TRIAL BY JURY IN RESPECT OF ANY ACTION, SUIT OR PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT, OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (i) NO
REPRESENTATIVE, AGENT OR ATTORNEY OF 

  
 6 

 
ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF SUCH ACTION, SUIT OR PROCEEDING, SEEK TO ENFORCE THE FOREGOING WAIVER, (ii) EACH
PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (iii) EACH PARTY MAKES THIS WAIVER VOLUNTARILY AND (iv) EACH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND
CERTIFICATIONS IN THIS SECTION 9(d). 
 (iii) The parties hereto agree that irreparable damage for which monetary
damages, even if available, would not be an adequate remedy, would occur in the event that the parties hereto do not perform their obligations under the provisions of this Agreement (including failing to take such actions as are required of them
hereunder) in accordance with its specified terms or otherwise breach such provisions. The parties acknowledge and agree that prior to the valid termination of this Agreement in accordance with Section 8, (a) the parties shall be
entitled to an injunction or injunctions, specific performance, or other equitable relief, to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof in the Chosen Courts without proof of damages or otherwise,
this being in addition to any other remedy to which they are entitled under this Agreement and (b) the right of specific enforcement is an integral part of the transactions contemplated by this Agreement and without that right, neither the
Company nor the Stockholders would have entered into this Agreement. Each of the parties hereto agrees that it will not oppose the granting of an injunction, specific performance and other equitable relief on the basis that (x) the other
parties hereto have an adequate remedy at Law or (y) an award of specific performance is not an appropriate remedy for any reason at Law or equity. The parties hereto acknowledge and agree that any party seeking an injunction or injunctions to
prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement in accordance with this Section 9(d)(iii) shall not be required to provide any bond or other security in connection with any such
order or injunction. 
 (e) Counterparts. This Agreement may be executed in any number of counterparts, each such
counterpart being deemed to be an original instrument, and all such counterparts shall together constitute one and the same agreement. 
 (f) Notices. Any notice, request, instruction or other document to be given hereunder by any party to the others shall be in writing and delivered personally or sent by registered or certified
mail, postage prepaid, by facsimile or by overnight courier:: 
 If to a Stockholder to: 

c/o KarpReilly, LLC 
 104 Field Point Road 
 Greenwich, CT 06830 

Attention: Allan Karp & Chris Reilly 
 Facsimile: 203-504-9912 

  
 7 

 with a copy (which shall not constitute notice) to: 

 

			
	Ropes & Gray LLP
	1211 Avenue of the Americas
	New York, NY 10036
	Attention: Daniel S. Evans
	Facsimile:	 	617-235-0028
	Email:	 	daniel.evans@ropesgray.com
	
	If to Company to:
	
	rue21, inc.
	800 Commonwealth Drive,
	Warrendale, PA 15086
	Attention:	 	Stacy Siegal, Senior Vice President, General Counsel and Chief
		 	Administrative Officer
	Facsimile:	 	(724) 776-9852
	Email:	 	ssiegal@rue21.com
	
	with a copy (which shall not constitute notice) to:
	
	Kirkland & Ellis LLP
	601 Lexington Avenue
	New York, NY 10022
	Attention:	 	David Fox
		 	David Feirstein
	Facsimile:	 	212-446-6460
	Email:	 	david.fox@kirkland.com
		 	david.feirstein@kirkland.com
	
	If to Parent to:
	
	        Apax Partners, L.P.,
	        601 Lexington Avenue, 53rd Floor.
	        New York, NY
	        Attention:	 	John Megrue
		 	Alex Pellegrini
	        Facsimile:	 	(646) 349-3306
	
	with a copy (which shall not constitute notice) to:
	
	        Simpson Thacher & Bartlett LLP
	        425 Lexington Avenue
	        New York, NY 10017
	        Attention:	 	Ryerson Symons
	        Facsimile:	 	(212) 455-2502
	        Email: rsymons@stblaw.com

  
 8 

 or to such other Persons or addresses as may be designated in writing by the party to receive such notice as
provided above. Any notice, request, instruction or other document given as provided above shall be deemed given to the receiving party upon actual receipt, if delivered personally; three Business Days after deposit in the mail, if sent by
registered or certified mail; upon confirmation of successful transmission if sent by facsimile (provided that if given by facsimile such notice, request, instruction or other document shall be followed up within one Business Day by dispatch
pursuant to one of the other methods described herein); or on the next Business Day after deposit with an overnight courier, if sent by a reputable nationwide overnight courier service. 

(g) NoThird Party Beneficiaries. This Agreement is not intended, and shall not be deemed, to confer any rights or remedies upon
any person other than the parties hereto and their respective successors and permitted assigns. 
 (h) Assignment. This
Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors, legal representatives and permitted assigns. Except in connection with any Transfer permitted by Section 3 hereof, no party
to this Agreement may assign any of its rights or delegate any of its obligations under this Agreement, by operation of Law or otherwise, without the prior written consent of the other party hereto (in the case of the Company, acting through the
Special Committee). Any purported assignment in violation of this Agreement is void. 
 (i) Interpretation. When
reference is made in this Agreement to a Section, such reference shall be to a Section of this Agreement, unless otherwise indicated. The headings contained in this Agreement are for convenience of reference only, do not constitute part of this
Agreement and shall not be deemed to limit or otherwise affect any of the provisions hereof. The parties have participated jointly in negotiating and drafting this Agreement. In the event that an ambiguity or a question of intent or interpretation
arises, this Agreement shall be construed as if drafted jointly by the parties, and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provision of this Agreement. Whenever the context
may require, any pronouns used in this Agreement shall include the corresponding masculine, feminine or neuter forms, and the singular form of nouns and pronouns shall include the plural, and vice versa. Whenever the words “include,”
“includes” or “including” are used in this Agreement, they shall be deemed to be followed by the words “without limitation.” No summary of this Agreement prepared by the parties shall affect in any way the meaning or
interpretation of this Agreement. All references to “dollars” or “$” in this Agreement are to United States dollars. All references to “days” shall be to calendar days unless otherwise indicated as a “Business
Day.” 
 [remainder of page left blank intentionally] 

  
 9 

 IN WITNESS WHEREOF, each of the parties hereto has caused this Agreement to be duly executed
individually or by its respective duly authorized officer as of the day and year first above written. 
  

			
	SKM EQUITY FUND II, L.P.
		
	By:	 	 SKM Partners, L.P.
 its General
Partner

		
	By:	 	 Saunders Karp & Megrue Partners, LLC
 its General Partner

		
	By:	 	 /s/ Christopher K. Reilly

		 	 Name: Christopher K. Reilly

Title: Authorized Signatory

	
	SKM INVESTMENT FUND II
		
	By:	 	 Saunders Karp & Megrue Partners, LLC
 its Managing Partner

		
	By:	 	 /s/ Christopher K. Reilly

		 	 Name: Christopher K. Reilly

Title: Authorized Signatory

	
	RUE21, INC.
		
	By:	 	 /s/ Robert N. Fisch

		 	 Name: Robert N. Fisch

Title: President, Chief Executive Officer

and Chairman of the Board

	
	 RHODES HOLDCO, INC. 
 (solely for purposes of Sections 1(a) hereof, and, to the extent applicable, Section 9 hereof)

		
	By:	 	 /s/ Alex Pellegrini

		 	 Name: Alex Pellegrini
 Title:
Vice President

 [Signature Page to Support Agreement] 

 SCHEDULE I 

 

					
	 Stockholder Name
	  	Number of
Subject
Shares of
Common
Stock	 
	 SKM Equity Fund II, L.P.
	  	 	6,952,861	  
	 SKM Investment Fund II
	  	 	139,057	  
	 Total
	  	 	7,091,918EX-4.2

 Exhibit 4.2 
 EVOKE PHARMA, INC. 
 INVESTOR RIGHTS AGREEMENT 

June 1, 2007 

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
			
	 SECTION 1.
	 	CERTAIN DEFINITIONS.	  	 	1	  
			
	 SECTION 2.
	 	COVENANTS OF THE COMPANY	  	 	3	  
			
	 2.1
	 	Financial Statements and Reports to Stockholders; Budget	  	 	3	  
			
	 2.2
	 	Inspection	  	 	3	  
			
	 2.3
	 	Confidentiality	  	 	4	  
			
	 2.4
	 	Proprietary Information and Inventions Agreements	  	 	4	  
			
	 2.5
	 	Restriction on Sales by Employees, Directors and Certain Stockholders	  	 	4	  
			
	 2.6
	 	Qualified Small Business	  	 	5	  
			
	 2.7
	 	Real Property Holding Corporation	  	 	5	  
			
	 2.8
	 	Board Meeting; Compensation of Directors	  	 	5	  
			
	 2.9
	 	Board Observer Rights	  	 	5	  
			
	 2.10
	 	Employee Stock	  	 	6	  
			
	 2.11
	 	Termination of Covenants	  	 	6	  
			
	 SECTION 3.
	 	REGISTRATION RIGHTS	  	 	6	  
			
	 3.1
	 	Demand Registration	  	 	6	  
			
	 3.2
	 	Piggyback Registration	  	 	10	  
			
	 3.3
	 	Expenses of Registration	  	 	11	  
			
	 3.4
	 	Registration Procedures	  	 	12	  
			
	 3.5
	 	Information Furnished by Holder	  	 	13	  
			
	 3.6
	 	Indemnification	  	 	13	  
			
	 3.7
	 	Limitations on Registration Rights Granted to Other Securities	  	 	15	  
			
	 3.8
	 	Transfer of Rights	  	 	15	  
			
	 3.9
	 	Market Stand-off	  	 	16	  
			
	 3.10
	 	Sale of Convertible Securities to Underwriter	  	 	16	  
			
	 3.11
	 	Rule 144 Requirements	  	 	16	  
			
	 3.12
	 	Termination of Company Agreements	  	 	16	  
			
	 SECTION 4.
	 	RIGHT OF FIRST REFUSAL	  	 	17	  
			
	 4.1
	 	Right of First Refusal	  	 	17	  
			
	 4.2
	 	Definition of New Securities	  	 	17	  
			
	 4.3
	 	Notices	  	 	18	  
			
	 4.4
	 	Failure to Exercise Right	  	 	18	  

  
 - i -

 TABLE OF CONTENTS 

(continued) 
  

							
	 	 	 	  	Page	 
			
	 4.5
	 	Rights of Affiliated Investors	  	 	18	  
			
	 4.6
	 	Assignment	  	 	18	  
			
	 4.7
	 	Termination	  	 	19	  
			
	 SECTION 5.
	 	TRANSFERS OF SECURITIES BY INVESTORS	  	 	19	  
			
	 5.1
	 	Notices	  	 	19	  
			
	 5.2
	 	Acceptance of Offer	  	 	19	  
			
	 5.3
	 	Allocation of Securities and Payment	  	 	19	  
			
	 5.4
	 	Failure to Exercise	  	 	20	  
			
	 5.5
	 	Assignment	  	 	20	  
			
	 5.6
	 	Permitted Transfers	  	 	20	  
			
	 5.7
	 	Termination	  	 	20	  
			
	 SECTION 6.
	 	MISCELLANEOUS	  	 	21	  
			
	 6.1
	 	Entire Agreement; Successors and Assigns	  	 	21	  
			
	 6.2
	 	Aggregation of Stock	  	 	21	  
			
	 6.3
	 	Governing Law	  	 	21	  
			
	 6.4
	 	Counterparts	  	 	21	  
			
	 6.5
	 	Headings	  	 	21	  
			
	 6.6
	 	Notices	  	 	21	  
			
	 6.7
	 	Amendment of Agreement; Waivers	  	 	21	  
			
	 6.8
	 	Additional Investors	  	 	21	  

  
 - ii -

 EVOKE PHARMA, INC. 

INVESTOR RIGHTS AGREEMENT 
 THIS INVESTOR RIGHTS AGREEMENT (this “Agreement”) is made as of June 1, 2007,
by and among EVOKE PHARMA, INC., a Delaware corporation (the “Company”), and each of the entities and persons listed on Schedule A hereto
(collectively, the “Investors”). 
 RECITALS 

A. The Investors are purchasing shares of the Company’s Series A Preferred Stock, par value $0.0001 per share (the “Series A
Preferred Stock”), pursuant to that certain Series A Preferred Stock Purchase Agreement of even date herewith (the “Purchase Agreement”). 
 B. The obligations in the Purchase Agreement are conditioned upon the execution and delivery of this Agreement. 
 THE PARTIES AGREE AS FOLLOWS: 
  

	SECTION 1.	CERTAIN DEFINITIONS. 

 As
used in this Agreement, the following terms shall have the following respective meanings: 
 (a) “Affiliate”
shall mean with respect to any Person, any Person which directly or indirectly through one or more intermediaries, controls, is controlled by or is under common control with such Person. 

(b) “Board” shall mean the Board of Directors of the Company. 

(c) “Commission” shall mean the Securities and Exchange Commission or any other federal agency at the time administering
the Securities Act. 
 (d) “Common Stock” shall mean the Company’s common stock, par value $0.0001 per
share. 
 (e) “Convertible Promissory Notes” shall mean those certain convertible promissory notes dated as of
March 12, 2007 issued by the Company in the aggregate principal amount of $250,000. 
 (f) “Convertible
Securities” shall mean the Company’s Series A Preferred Stock. 
 (g) “Form S-3” shall mean Form
S-3 issued by the Commission or any substantially similar form then in effect. 
 (h) “Holder” shall mean any
Person entering into this Agreement and any holder of outstanding Registrable Securities or an assignee or transferee of Registration rights as permitted by Section 3.8. 
 (i) “Initiating Holders” shall mean Holders who in the aggregate hold more than fifty percent (50%) of the Registrable Securities, excluding shares under clause (ii) of the
definition of “Registrable Securities” below. 

 (j) “Material Adverse Event” shall mean an occurrence having a consequence
that either (a) is materially adverse as to the business, properties, prospects or financial condition of the Company or (b) is reasonably foreseeable, has a reasonable likelihood of occurring, and if it were to occur would reasonably be
expected to materially adversely affect the business, properties, prospects or financial condition of the Company. 
 (k)
“Person” shall mean an individual, a corporation, a partnership, a trust or unincorporated organization or any other entity or organization. 
 (l) “Qualified Public Offering” shall mean a firmly underwritten public offering of the Company’s Common Stock Registered under the Securities Act and (i) involving gross
proceeds to the Company of at least Twenty Five Million Dollars ($25,000,000) (prior to deduction for underwriters’ discounts and other expenses relating to such public offering, including, without limitation, fees of the Company’s
counsel) and the price to the public is at least Four Dollars and Fifty Cents ($4.50) per share (equitably adjusted for all stock splits, sub-divisions, stock dividends, combinations and the like with respect to such shares) or (ii) approved by
holders of at least sixty-six and two-thirds percent (66 2/3%) of the then outstanding shares of Series A Preferred Stock. 

(m) The terms “Register,” “Registered” and “Registration” refer to a registration
effected by preparing and filing a registration statement in compliance with the Securities Act (“Registration Statement”), and the declaration or ordering of the effectiveness of such Registration Statement. 

(n) “Registrable Securities” shall mean (i) all Common Stock not previously sold to the public issued or issuable
upon conversion of any of the Convertible Securities purchased by or issued to the Investors, (ii) all of the shares of Common Stock owned by the Investors, (iii) any shares of Common Stock issued or issuable upon conversion of any
Convertible Securities granted registration rights pursuant to Section 3.7 of this Agreement, and (iv) any Common Stock of the Company issued as (or issuable upon the conversion or exercise of any warrant, right or other security that is
issued as) a dividend or other distribution with respect to, or in exchange for, or in replacement of, the Common Stock described in clauses (i) through (iii) of this definition. 

(o) “Registration Expenses” shall mean all expenses incurred by the Company in complying with Sections 3.1 or 3.2 of
this Agreement, including, without limitation, all federal and state registration, qualification and filing fees, printing expenses, fees and disbursements of counsel for the Company and fees and disbursements, in an aggregate amount not to exceed
$25,000, of not more than one (1) special counsel for the Holders, blue sky fees and expenses, and the expense of any special audits incident to or required by any such Registration. 

(p) “Securities Act” shall mean the Securities Act of 1933, as amended, or any similar federal statute, and the rules
and regulations of the Commission thereunder, all as the same shall be in effect at the time. 
 (q) “Selling
Expenses” shall mean all underwriting discounts and selling commissions applicable to the sale of Registrable Securities pursuant to this Agreement. 
 (r) “Special Registration Statement” shall mean (i) a registration statement relating to any employee benefit plan, (ii) with respect to any corporate reorganization or
transaction under Rule 145 of the Securities Act, including any registration statements related to the resale of securities issued in such a transaction, or (iii) a registration related to stock issued upon conversion of debt securities.

  
 - 2 -

	SECTION 2.	COVENANTS OF THE COMPANY 

2.1 Financial Statements and Reports to Stockholders; Budget. For so long as an Investor or subsequent holder of Convertible
Securities holds or is deemed to hold at least Two Hundred Fifty Thousand (250,000) shares of Registrable Securities (equitably adjusted for all stock splits, subdivisions, stock dividends, combinations and the like with respect to such
shares), the Company shall deliver to each Investor: 
 (a) As soon as practicable after the end of each fiscal year, and in any
event within one hundred twenty (120) days thereafter, audited consolidated balance sheets of the Company and its subsidiaries, if any, as of the end of such fiscal year, and consolidated statements of income, stockholders’ equity and
consolidated statements of cash flow of the Company and its subsidiaries, if any, for such year, prepared in accordance with generally accepted accounting principles, consistently applied, and setting forth in each case in comparative form the
figures for the previous fiscal year, all in reasonable detail. Such financial statements shall be accompanied by a report and opinion thereon by independent public accountants of national standing selected by the Board. 

(b) As soon as practicable after the end of each fiscal quarter, and in any event within forty-five (45) days after the end of each
such fiscal quarter, an unaudited consolidated balance sheet of the Company as at the end of such quarter, and unaudited consolidated statements of income, stockholders’ equity and statements of cash flow for such quarter and for the current
fiscal year to date. Such financial statements shall be prepared in accordance with generally accepted accounting principles consistently applied (other than accompanying notes and subject to normal year-end adjustments), all in reasonable detail,
including detailed quarterly comparisons to budget. 
 (c) As soon as practicable after the end of each month, and in any event
within thirty (30) days after the end of each such month, an unaudited consolidated balance sheet of the Company as at the end of such month, and unaudited consolidated statements of income, stockholders’ equity and statements of cash flow
for such month and for the current fiscal year to date. Such financial statements shall be prepared in accordance with generally accepted accounting principles consistently applied (other than accompanying notes and subject to year-end adjustments),
all in reasonable detail, including detailed monthly comparisons to budget. 
 (d) As soon as practicable, and in any event
within thirty (30) days prior to the beginning of the fiscal year, a copy of the Company’s annual operating plan and budget for the upcoming fiscal year, which shall include without limitation forecasts of the Company’s revenues,
expenses and cash position on a month-to-month basis for such upcoming fiscal year together with any other budgets or revised budgets as they become available throughout the fiscal year. 

(e) Contemporaneously with delivery to holders of Common Stock, a copy of each report of the Company delivered to holders of Common
Stock. 
 2.2 Inspection. For so long as an Investor or subsequent holder of Convertible Securities holds or is deemed to
hold at least Two Hundred Fifty Thousand (250,000) shares of Registrable Securities (equitably adjusted for all stock splits, subdivisions, stock dividends, combinations and the like with respect to such shares), the Company shall permit such
Investor, at such Investor’s expense, to visit and inspect the Company’s properties, to examine its books of account and records and to discuss the Company’s affairs, finances and accounts with its officers, all at such reasonable
times and as often as may be reasonably requested by each such Investor; provided, however, that the Company shall not be obligated pursuant to this Section 2.2 with respect to a competitor of the Company or with respect to any
information which it reasonably considers to be a trade secret or confidential information. The rights of an 

  
 - 3 -

 
Investor under this Section 2.2 may not be assigned as part of such Investor’s sale of any of the Registrable Securities or Convertible Securities except with the consent of the
Company, which consent shall not be unreasonably withheld. 
 2.3 Confidentiality. Each Investor agrees and will cause
any representative of the Investor to hold in confidence and trust and not use or disclose any information provided to or learned by it in connection with its rights under this Section 2, except that such Investor may disclose such information
to any general partner, limited partner, member, subsidiary or parent (and their respective representatives) of such Investor for the purpose of evaluating its investment in the Company as long as (a) such general partner, limited partner,
member, subsidiary or parent is advised of the confidentiality provisions of this Section 2.3 and (b) such Investor uses its commercially reasonable best efforts to ensure that such general partner, limited partner, member, subsidiary or
parent holds such information in confidence and trust and will not use or disclose any information provided to or learned by it except as required by law. Notwithstanding the foregoing, however, the obligation of each Investor to hold information
confidential as provided herein or any other document or agreement relating thereto shall not prohibit such Investor from disclosing such information: (i) to its board of directors, investment advisers, attorneys, accountants, consultants and
other professionals to the extent necessary to obtain their services in connection with its investment in the Company, provided that such persons agree to hold such information confidential as provided herein and in such provisions (as
modified by this paragraph); (ii) to any prospective purchaser of any shares of the Company owned by such Investor as long as such prospective purchaser agrees in writing to be bound by the confidentiality provisions as provided herein or in
such provisions (as modified by this paragraph); (iii) to such Investor’s investment advisor or any investment companies managed by such Investor’s investment advisor, provided that such persons agree to hold such information
confidential as provided herein or in such provisions (as modified by this paragraph); or (iv) as required by applicable law or regulation, regulatory body, stock exchange, court or administrative order, or any listing or trading agreement
concerning such Investor or the Company. Furthermore, nothing in this Section 2.3 shall restrict any Investor’s ability to disclose the existence or nature of its relationship with the Company, the nature or amount of its investment in
securities of the Company or to provide its affiliates with quarterly, annual or other reports and such other information about the Company prepared by such Investor in the ordinary course of its business, provided that said Investor takes
commercially reasonable measures to ensure that any such affiliates protect the confidential nature of such confidential information. The Company understands that the Investors are in the business of making investments in early stage companies
involved in various life science fields and, therefore, engage in discussions with numerous entities that are seeking capital. The Residuals resulting from access to or work with such confidential information shall not be subject to the
confidentiality and non-use obligations contained in this Agreement. For the purposes hereof, the term “Residuals” means know-how and experience gained from the information delivered by the Company to the Investors hereunder, and
retained in the unaided memories of the Investors without reference to any material that is written, stored in magnetic, electronic or physical form or otherwise fixed. “Residuals” specifically excludes any works protected by
patent. 
 2.4 Proprietary Information and Inventions Agreements. The Company agrees to require each employee and officer
of the Company to execute a proprietary information and inventions agreement and each consultant and advisor of the Company to execute an agreement that provides for confidential treatment of the Company’s proprietary information as a condition
of employment or engagement or continued employment or engagement, as the case may be, unless otherwise approved by the Board. 

2.5 Restriction on Sales by Employees, Directors and Certain Stockholders. The Company and Holders agree that, until the time of a
Qualified Public Offering, first, the Company, and second, the Investors will have a right of first refusal on all transfers of Common Stock by employees, directors and stockholders who individually, or together with his, her or its Affiliates, hold
more than one percent (1%) of the outstanding capital stock of the Company (“1% Stockholders”), subject to transfers to family 

  
 - 4 -

 
members or trusts for the benefit of family members and other limited exceptions as determined by the Board. The Company agrees to include appropriate language to this effect in its Bylaws or in
future employment agreements, stock option and/or restricted stock grants, or other similar agreements with employees, directors and 1% Stockholders, as applicable. 
 2.6 Qualified Small Business. The Company covenants that so long as any Convertible Securities, or the Common Stock into which such shares are converted, are held by a Holder in whose hands such
shares of Common Stock are eligible to qualify as “qualified small business stock” as defined in Section 1202(c) of the of the Internal Revenue Code of 1986, as amended (the “Code”) (“Qualified Small Business
Stock”), it will (i) comply with any applicable filing or reporting requirements imposed by the Code on issuers of Qualified Small Business Stock and (ii) execute and deliver to each Holder, from time to time, such forms,
documents, schedules and other instruments as may be reasonably requested thereby to cause the Convertible Securities, or the Common Stock into which such shares are converted, to qualify as Qualified Small Business Stock. 

2.7 Real Property Holding Corporation. The Company is not a “United States real property holding corporation,” as that
term is defined in Internal Revenue Code (“IRC”) Section 897(c)(2) and Treasury Regulation Section 1.897-2(b). If at any time in the future the Company shall become a “United States real property holding
corporation,” the Company shall notify each foreign investor of such event as promptly as practicable. Within thirty (30) days after receipt of a request from a foreign investor, the Company shall prepare and deliver to such foreign
investor the statement required under Treasury Regulation Section 1.897-2(h) and, subject to the succeeding sentence, either or both of the following documents: (i) an affidavit in conformance with the requirements of IRC
Section 1445(b)(3) and the regulations thereunder or (ii) a notarized statement, executed by an officer having actual knowledge of the facts, that the shares of Company stock held by such foreign investor are of a class that is regularly
traded on an established securities market, within the meaning of IRC Section 1445(b)(6) and the regulations thereunder. If the Company is unable to provide either of the documents described in (i) or (ii) above upon request, it shall
promptly, in any event within thirty (30) days, notify such foreign investor in writing of the reason for such inability. Finally, upon the request of a foreign investor and without regard to whether either document described in (i) or
(ii) above has been requested, the Company shall reasonably cooperate with the efforts of such foreign investor to obtain a “qualifying statement” within the meaning of IRC Section 1445(b)(4) and the regulations thereunder or
such other documents as would excuse a transferee of a foreign investor’s interest from withholding of income tax imposed pursuant to IRC Section 897(a). 
 2.8 Board Meeting; Compensation of Directors. The Company hereby covenants that so long as the holders of the Convertible Securities are entitled to appoint any members of the Board pursuant to the
Company’s Restated Certificate of Incorporation, as amended, the Board shall not meet less frequently than quarterly. All non-employee directors will be compensated by the Company identically; provided however, that additional
compensation may be provided to the Chairman of the Board or the Chairman of any Committee of the Board; provided, that such compensation is approved by the Board. All out-of-pocket and travel expenses of the directors incurred in attending
Board meetings (or meetings of committees thereof) or in connection with the performance of their duties as directors shall be paid or reimbursed promptly by the Company. The Company shall also agree to indemnify each of its officers and directors
to the fullest extent permitted by the Delaware General Corporation Law and enter into customary indemnification agreements with each of its officers and directors evidencing such indemnification obligation. 

2.9 Board Observer Rights. For so long as an Investor or subsequent holder of Convertible Securities holds or is deemed to hold
(or is obligated to purchase under the Purchase Agreement) an aggregate of at least Two Million (2,000,000) shares of Registrable Securities (equitably adjusted for 

  
 - 5 -

 
all stock splits, subdivisions, stock dividends, combinations and the like with respect to such shares), the Company shall allow one representative designated by such Investor (the
“Observer”) to attend meetings of the Board in a non-voting capacity. The Company shall provide the Observer with copies of all materials that are provided by the Company to its directors; provided, however, that a majority
of the members of the Board shall be entitled to recuse the Observer from portions of any Board meeting and to redact portions of any Board or Board committee materials delivered to the Observer where and to the extent that such majority determines,
in good faith that (i) such recusal is reasonably necessary, in the opinion of counsel to the Company, to preserve attorney-client privilege with respect to a material matter, (ii) there exists, with respect to any deliberation or Board
materials, an actual or potential conflict of interest between the Investor who has appointed such Observer and the Company or (iii) the presence of the Observer would otherwise be materially injurious to the Company in such circumstances. Any
Observer will be subject to the confidentiality provisions set forth in Section 2.3. The Observer shall receive no compensation from the Company for service as an Observer and shall not be reimbursed for any expenses incurred by the Observer in
connection with attendance of any meeting of the Board. 
 2.10 Employee Stock. With respect to any shares issued or
options or rights granted to employees after the date hereof, unless otherwise approved by the Board, the Company shall cause each employee of the Company to enter into an agreement providing for vesting of such shares or options or rights over
forty-eight (48) months, with no shares or options or rights being vested for twelve (12) months from the date of commencement of services in the case of stock or option grants for new hires, or the date of issuance or grant in the case of
subsequent stock or option grants, at which time 1/4th of the shares or options or rights shall be vested and 1/36th of the remaining shares, options or rights shall be vested monthly thereafter. Any options providing for early exercise and any
grant of restricted stock shall provide for a repurchase option so that upon termination of the employment relationship of the stockholder, the Company or its assignee (to the extent permissible under applicable securities law qualification) retains
the option to repurchase at cost any unvested shares held by such stockholder. 
 2.11 Termination of Covenants. The
covenants of the Company set forth in this Section 2 shall be terminated and be of no further force or effect upon the earlier of (a) the closing of the first Qualified Public Offering, (b) the closing of a sale, lease, or other
disposition of all or substantially all of the Company’s assets or the Company’s merger into or consolidation with any other corporation or other entity, or any other corporate reorganization, in which the holders of the Company’s
outstanding voting stock immediately prior to such transaction own, immediately after such transaction, securities representing less than fifty percent (50%) of the voting power of the corporation or other entity surviving such transaction,
provided that this Section 2.11 shall not apply to a merger effected exclusively for the purpose of changing the domicile of the Company or a sale of shares by the Company for primarily equity financing purposes, and (c) the date
when no shares of Registrable Securities or Convertible Securities shall be outstanding. 
  

	SECTION 3.	REGISTRATION RIGHTS 

 3.1
Demand Registration. 
 3.1.1. Request for Registration on Form other than Form S-3. Subject to the terms of this
Agreement, in the event that the Company shall receive from the Initiating Holders at any time after the earlier of (i) three (3) years after the date of this Agreement and (ii) six (6) months after the effective date of the
Company’s initial public offering of shares of Common Stock under a Registration Statement, a written request that the Company effect any Registration with respect to all or a part of the Registrable Securities on a form other than Form S-3 for
an offering reasonably anticipated to have an aggregate offering price to the public which would exceed Five Million Dollars ($5,000,000), the Company shall (i)

  
 - 6 -

 
promptly give written notice of the proposed Registration to all other Holders and shall (ii) as soon as practicable, use its reasonable best efforts to effect Registration of the
Registrable Securities specified in such request, together with any Registrable Securities of any Holder joining in such request as are specified in a written request given within twenty (20) days after written notice from the Company. The
Company shall not be obligated to take any action to effect any such Registration pursuant to this Section 3.1.1: 
 (i)
after the Company has effected two (2) such Registrations pursuant to this Section 3.1.1 and such Registrations have been declared effective; provided that either (A) the conditions of Section 3.4(a) have been satisfied or
(B) the registration statements continue to remain effective and there are no stop orders in effect with respect to such registration statements; 
 (ii) during the period starting with the date of filing of, and ending on the date one hundred eighty (180) days following the effective date of the registration statement pertaining to the
Company’s initial public offering, other than pursuant to a Special Registration Statement; provided that the Company makes reasonable good faith efforts to cause such registration statement to become effective; 

(iii) if within thirty (30) days of receipt of a written request from the Initiating Holders pursuant to Section 3.1.1, the
Company gives notice to the Holders of the Company’s intention to file a registration statement for a public offering, other than pursuant to a Special Registration Statement, within ninety (90) days; or 

(iv) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3
pursuant to a request made pursuant to Section 3.1.3 below. 
 3.1.2. Right of Deferral of Registration on Form other
than Form S-3. If the Company shall furnish to all such Holders who joined in the request a certificate signed by the President of the Company stating that, in the good faith judgment of the Board, it would be seriously detrimental to the
Company for any Registration to be effected as requested under Section 3.1.1, the Company shall have the right to defer the filing of a Registration Statement with respect to such offering for a period of not more than ninety (90) days
from delivery of the request of the Initiating Holders; provided, however, that the Company may not utilize this right more than once in any twelve (12)-month period. 
 3.1.3. Request for Registration on Form S-3. Subject to the terms of this Agreement, in the event that the Company receives from one or more Holders a written request that the Company effect any
Registration on Form S-3 (or any successor form to Form S-3 regardless of its designation) at a time when the Company is eligible to Register securities on Form S-3 (or any successor form to Form S-3 regardless of its designation) for an offering of
Registrable Securities which such Holders in their good faith discretion determine would have an anticipated offering price of at least One Million Dollars ($1,000,000), the Company will promptly give written notice of the proposed Registration to
all the Holders and will as soon as practicable use its best efforts to effect Registration of the Registrable Securities specified in such request, together with all or such portion of the Registrable Securities of any Holder joining in such
request as are specified in a written request delivered to the Company within thirty (30) days after written notice from the Company of the proposed Registration. There shall be no limit to the number of occasions on which the Company shall be
obligated to effect Registration under this Section 3.1.3, but the Company shall not be required to effect more than two (2) such Registrations in any twelve (12)-month period. Notwithstanding the foregoing, the Company shall not be
obligated to effect any Registration pursuant to this Section 3.1.3: 
 (i) if Form S-3 is not available for such offering
by the Holders; 

  
 - 7 -

 (ii) if the Holders, together with the holders of any other securities of the Company
entitled to inclusion in such registration, propose to sell Registrable Securities and such other securities (if any) at an aggregate price to the public of less than One Million Dollars ($1,000,000); 

(iii) if within thirty (30) days of receipt of a written request from any Holder or Holders pursuant to this Section 3.1.3,
the Company gives notice to such Holder or Holders of the Company’s intention to make a public offering within ninety (90) days, other than pursuant to a Special Registration Statement; or 

(iv) if the Company shall furnish to the Holders a certificate signed by the President of the Company stating that, in the good faith
judgment of the Board, it would be seriously detrimental to the Company for any Registration to be effected as requested under Section 3.1.3, the Company shall have the right to defer the filing of a Registration Statement with respect to such
offering for a period of not more than ninety (90) days from delivery of the request of the Holders requesting such Registration; provided, however, that the Company may not utilize this right more than once in any twelve (12)-month
period. 
 3.1.4. Registration of Other Securities in Demand Registration. Any Registration Statement filed pursuant to
the request of the Initiating Holders under this Section 3 may, subject to the provisions of Section 3.1.5, include securities of the Company other than Registrable Securities. 

3.1.5. Underwriting in Demand Registration. 
 a. Notice of Underwriting. 
 If the Initiating Holders intend to
distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company, as a part of their request made pursuant to this Section 3.1, and the Company shall include such information in the
written notice referred to in Section 3.1.1 or 3.1.3. The right of any Holder to Registration pursuant to Section 3 shall be conditioned upon such Holder’s agreement to participate in such underwriting and the inclusion of such
Holder’s Registrable Securities in the underwriting. 
 b. Inclusion of other Holders in Demand Registration.

 If the Company, officers or directors of the Company holding Common Stock other than Registrable Securities or holders of
securities issued by the Company other than Registrable Securities, request inclusion in such Registration, the Initiating Holders, to the extent they deem advisable and consistent with the goals of such Registration, shall, on behalf of all
Holders, offer to any or all of the Company, such officers or directors and such holders of securities other than Registrable Securities that such securities other than Registrable Securities be included in the underwriting and may condition such
offer on the acceptance by such persons of the terms of this Section 3.1. 
 c. Selection of Underwriter in Demand
Registration. 
 The Company shall (together with all Holders proposing to distribute their securities through such
underwriting) enter into an underwriting agreement with the representative (“Underwriter’s Representative”) of the underwriter or underwriters selected for such underwriting by the Holders of a majority of the Registrable
Securities being Registered by the Initiating Holders and agreed to by the Company, which agreement shall not be unreasonably withheld or delayed. 

  
 - 8 -

 d. Marketing Limitation in Demand Registration. 

In the event the Underwriter’s Representative advises the Initiating Holders in writing that market factors (including, without
limitation, the aggregate number of shares of Common Stock requested to be Registered, the general condition of the market, and the status of the persons proposing to sell securities pursuant to the Registration) require a limitation of the number
of shares to be underwritten, then (i) first the securities other than Registrable Securities and (ii) next the securities requested to be registered by the Company, shall be excluded from such Registration to the extent required by such
limitation. If a limitation of the number of shares is still required, the Initiating Holders shall so advise all Holders and the number of shares of Registrable Securities that may be included in the Registration and underwriting shall be allocated
among all Holders in proportion, as nearly as practicable, to the respective amounts of Registrable Securities entitled to inclusion in such Registration held by such Holders at the time of filing the Registration Statement. No Registrable
Securities or other securities excluded from the underwriting by reason of this Section 3.1.5(d) shall be included in such Registration Statement. To facilitate the allocation of shares in accordance with the above provisions, the Company or
the Underwriter’s Representative may round the number of shares allocated to any Holder to the nearest one hundred (100) shares. 
 e. Right of Withdrawal in Demand Registration. 
 If any Holder of
Registrable Securities, or a holder of other securities entitled (upon request) to be included in such Registration, disapproves of the terms of the underwriting, such person may elect to withdraw therefrom by written notice to the Company, the
underwriter and the Initiating Holders delivered at least seven (7) business days prior to the effective date of the Registration Statement. The securities so withdrawn shall also be withdrawn from the Registration Statement. 

3.1.6. Blue Sky in Demand Registration. In the event of any Registration pursuant to Section 3.1, the Company will exercise
its reasonable best efforts to Register and qualify the securities covered by the Registration Statement under such other securities or Blue Sky laws of such jurisdictions as shall be reasonably appropriate for the distribution of such securities;
provided, however, that (i) the Company shall not be required to qualify to do business or to file a general consent to service of process in any such states or jurisdictions, and (ii) notwithstanding anything in this Agreement to
the contrary, in the event any jurisdiction in which the securities shall be qualified imposes a non-waivable requirement that expenses incurred in connection with the qualification of the securities be borne by selling stockholders, such expenses
shall be payable pro rata by selling stockholders. 

  
 - 9 -

 3.2 Piggyback Registration. 

3.2.1. Notice of Piggyback Registration and Inclusion of Registrable Securities. Subject to the terms of this Agreement, in the
event the Company decides to Register any of its Common Stock (either for its own account or the account of a security holder or holders exercising their respective demand Registration rights) on a form (other than a Registration on Form S-4 and
Form S-8, as those forms are issued by the Commission or any substantially similar forms then in effect) that would be suitable for a Registration involving solely Registrable Securities, the Company will: (i) promptly give each Holder written
notice thereof (which shall include a list of the jurisdictions in which the Company intends to attempt to qualify such securities under the applicable Blue Sky or other state securities laws) and (ii) include in such Registration (and any
related qualification under Blue Sky laws or other compliance), and in any underwriting involved therein, all the Registrable Securities specified in a written request delivered to the Company by any Holder within fifteen (15) days after
delivery of such written notice from the Company. 
 3.2.2. Underwriting in Piggyback Registration. 

a. Notice of Underwriting in Piggyback Registration. 
 If the Registration of which the Company gives notice pursuant to Section 3.2.1 is for a Registered public offering involving an underwriting, the Company shall so advise the Holders as a part of the
written notice given pursuant to Section 3.2.1. In such event the right of any Holder to Registration shall be conditioned upon such underwriting and the inclusion of such Holder’s Registrable Securities in such underwriting to the extent
provided in this Section 3. All Holders proposing to distribute their securities through such underwriting shall (together with the Company and the other holders distributing their securities through such underwriting) enter into an
underwriting agreement with the Underwriter’s Representative for such offering. The Holders shall have no right to participate in the selection of the underwriters for an offering pursuant to this Section 3.2. 

b. Marketing Limitation in Piggyback Registration. 
 In the event the Underwriter’s Representative advises the Holders seeking Registration of Registrable Securities pursuant to Section 3.2 in writing that market factors (including, without
limitation, the aggregate number of shares of Common Stock requested to be Registered, the general condition of the market, and the status of the persons proposing to sell securities pursuant to the Registration) require a limitation of the number
of shares to be underwritten, the Underwriter’s Representative (subject to the allocation priority set forth in Section 3.2.2(c)) may: 
 i. in the case of the Company’s initial Registered public offering, exclude some or all Registrable Securities from such Registration and underwriting; and 

ii. in the case of any subsequent registered public offering, limit the number of shares of Registrable Securities to be included in
such Registration and underwriting to not less than twenty percent (20%) of the securities included in such Registration (based on aggregate market values). 
 c. Allocation of Shares in Piggyback Registration. 
 In the event that the
Underwriter’s Representative limits the number of shares to be included in a Registration pursuant to Section 3.2.2(b), the number of shares to be included in such Registration shall be allocated (subject to Section 3.2.2(b)) in the
following manner: The number of 

  
 - 10 -

 
shares, if any, that may be included in the Registration and underwriting by selling stockholders shall first be allocated among all the requesting Holders pro rata according to the respective
amounts of Registrable Securities entitled to be included in such offering by such requesting Holders and then among all other holders of securities other than Registrable Securities requesting and legally entitled to include shares in such
Registration, in proportion, as nearly as practicable, to the respective amounts of securities (including Registrable Securities) which such Holders and such other holders would otherwise be entitled to include in such Registration. No Registrable
Securities or other securities excluded from the underwriting by reason of this Section 3.2.2(c) shall be included in the Registration Statement. To facilitate the allocation of shares in accordance with the above provisions, the Company or the
Underwriter’s Representative may round the number of shares allocated to any Holder to the nearest one hundred (100) shares. 
 d. Withdrawal in Piggyback Registration. 
 If any Holder disapproves of
the terms of any such underwriting, he may elect to withdraw therefrom by written notice to the Company and the underwriter delivered at least seven (7) business days prior to the effective date of the Registration Statement. Any Registrable
Securities or other securities excluded or withdrawn from such underwriting shall be withdrawn from such Registration. 
 3.2.3.
Blue Sky in Piggyback Registration. In the event of any Registration of Registrable Securities pursuant to Section 3.2, the Company will exercise its best efforts to Register and qualify the securities covered by the Registration
Statement under such other securities or Blue Sky laws of such jurisdictions as shall be reasonably appropriate for the distribution of such securities; provided, however, that (i) the Company shall not be required to qualify to do
business or to file a general consent to service of process in any such states or jurisdictions, and (ii) notwithstanding anything in this Agreement to the contrary, in the event any jurisdiction in which the securities shall be qualified
imposes a non-waivable requirement that expenses incurred in connection with the qualification of the securities be borne by selling stockholders, such expenses shall be payable pro rata by selling stockholders. 

3.3 Expenses of Registration. All Registration Expenses incurred in connection with two (2) Registrations pursuant to
Section 3.1.1, all Registrations pursuant to Section 3.1.3 (Form S-3) and all Registrations pursuant to Section 3.2 shall be borne by the Company. All Registration Expenses incurred in connection with any other registration,
qualification or compliance shall be apportioned among the Holders and other holders of the securities so registered on the basis of the number of shares so registered. Notwithstanding the above, the Company shall not be required to pay for any
expenses of any Registration proceeding begun pursuant to Section 3.1 if the Registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be Registered (which Holders shall bear
such expenses), unless the Holders of a majority of the Registrable Securities agree to forfeit their right to one (1) demand Registration pursuant to Section 3.1; provided further, however, that if at the time of such withdrawal,
the Holders have learned of a Material Adverse Event either (i) not known to the Holders at the time of their request or (ii) not made known to the Holders within fifteen (15) days after their request, then the Holders shall not be
required to pay any of such expenses and shall retain their rights pursuant to Section 3.1. All Selling Expenses relating to securities held by stockholders and being sold in such registration shall be borne by the respective holders of such
securities Registered pro rata on the basis of the number of shares registered. 

  
 - 11 -

 3.4 Registration Procedures. In the case of each registration, qualification or
compliance effected by the Company pursuant to this Section 3, the Company will: 
 (a) Keep each Holder whose Registrable
Securities are included in any Registration pursuant to this Agreement advised as to the initiation and completion of such Registration. At its expense the Company will: (i) use its best efforts to keep such Registration effective for a period
of one hundred twenty (120) days or until the Holder or Holders have completed the distribution described in the Registration Statement relating thereto, whichever first occurs; and (ii) furnish such number of prospectuses (including
preliminary prospectuses) in conformity with the Securities Act and such other documents as a Holder from time to time may reasonably request. With respect to clause (i) of the preceding sentence, the Company may at any time upon written notice
to the participating Holders and for a period not to exceed sixty (60) days thereafter (the “Suspension Period”) delay the filing or effectiveness of any registration statement or suspend the use or effectiveness of any
registration statement (and the Holders hereby agree not to offer or sell any Registrable Securities pursuant to such registration statement during the Suspension Period) if the Company reasonably believes that the Company may, in the absence of
such delay or suspension hereunder, be required under state or federal securities laws to disclose any corporate development the disclosure of which could reasonably be expected to have an adverse effect upon the Company, its stockholders, a
potentially significant transaction or event involving the Company, or any negotiations, discussions, or proposals directly relating thereto. In the event that the Company shall exercise its rights hereunder, the applicable time period during which
the registration statement is to remain effective shall be extended by a period of time equal to the duration of the Suspension Period. The Company may extend the Suspension Period for an additional consecutive sixty (60) days with the consent
of the holders of a majority of the Registrable Securities proposed to be sold by the Holders in the applicable Registration, which consent shall not be unreasonably withheld. If so directed by the Company, the Holders shall use their best efforts
to deliver to the Company (at the Company’s expense) all copies, other than permanent file copies then in such Holders’ possession, of the prospectus relating to such Registrable Securities current at the time of receipt of such notice.

 (b) Prepare and file with the Commission such amendments and supplements to such registration statement and the prospectus
used in connection with such registration statements as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such registration statement for the periods specified in
Section 3.4(a) above; 
 (c) Promptly notify each Holder of Registrable Securities covered by the registration statement at
any time when the Company becomes aware of the happening of any event as a result of which the registration statement or the prospectus included in such registration statement or any supplement to the prospectus (as then in effect) contains any
untrue statement of a material fact or omits to state a material fact necessary to make the statements therein (in the case of the prospectus, in light of the circumstances under which they were made) not misleading or, if for any other reason it
shall be necessary during such time period to amend or supplement the registration statement or the prospectus in order to comply with the Securities Act, whereupon, in either case, each Holder shall immediately cease to use such registration
statement or prospectus for any purpose and, as promptly as practicable thereafter, the Company shall prepare and file with the Commission, and furnish without charge to the appropriate Holders and managing underwriters, if any, a supplement or
amendment to such registration statement or prospectus which will correct such statement or omission or effect such compliance and such copies thereof as the Holders and any underwriters may reasonably request; 

(d) Use its best efforts to register and qualify the securities covered by such registration statement under such other securities or
Blue Sky laws of such jurisdictions as shall be reasonably requested by the Holders, provided that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to file a general consent to
service of process in any such states or jurisdictions except as may be required by law; 

  
 - 12 -

 (e) Cause all such Registrable Securities to be listed on each securities exchange on which
similar securities issued by the Company are then listed; 
 (f) Provide a transfer agent and registrar for all Registrable
Securities and a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration; 
 (g) In the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the managing underwriter of such offering.
Each Holder participating in such underwriting shall also enter into and perform its obligations under such an agreement; and 

(h) Use its best efforts to furnish, at the request of any Holder requesting registration of Registrable Securities pursuant to this
Section 3, on the date that such Registrable Securities are delivered to the underwriters for sale in connection with a registration pursuant to this Section 3, if such securities are being sold through underwriters, or, if such securities
are not being sold through underwriters, on the date that the registration statement with respect to such securities becomes effective, (i) an opinion, dated such date, of the counsel representing the Company for the purposes of such
registration, in form and substance as is customarily given to underwriters in an underwritten public offering, addressed to the underwriters, if any, and to the Holders requesting registration of Registrable Securities and (ii) a letter dated
such date, from the independent certified public accountants of the Company, in form and substance as is customarily given by independent certified public accountants to underwriters in an underwritten public offering, addressed to the underwriters,
if any, and to the Holders requesting registration of Registrable Securities (to the extent the then applicable standards of professional conduct permit said letter to be addressed to the Holders). 

3.5 Information Furnished by Holder. It shall be a condition precedent of the Company’s obligations under this Agreement that
each Holder of Registrable Securities included in any Registration furnish to the Company such information regarding such Holder and the distribution proposed by such Holder or Holders as the Company may reasonably request. 

3.6 Indemnification. 
 3.6.1. Company’s Indemnification of Holders. To the extent permitted by law, the Company will indemnify each Holder, each of its officers, directors and constituent partners, members,
managers, legal counsel for the Holders, and each person controlling such Holder, with respect to which Registration, qualification or compliance of Registrable Securities has been effected pursuant to this Agreement, and each underwriter, if any,
and each person who controls any underwriter, against all claims, losses, damages or liabilities (or actions in respect thereof) to the extent such claims, losses, damages or liabilities arise out of or are based upon any untrue statement (or
alleged untrue statement) of a material fact contained in any prospectus or other document (including any related Registration Statement) incident to any such Registration, qualification or compliance, or are based on any omission (or alleged
omission) to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, or any violation by the Company of any rule or regulation promulgated under the Securities Act or Exchange Act or
state or federal law applicable to the Company and relating to action or inaction required of the Company in connection with any such Registration, qualification or compliance; and the Company will reimburse each such Holder, each of its officers,
directors and constituent partners, members, managers, legal counsel for the Holders, each such underwriter and each person who controls any such Holder or underwriter for any legal and any other expenses reasonably incurred in connection with
investigating or defending any such claim, loss, damage, liability or action; provided, however, that the indemnity contained in this Section 3.6.1 shall not apply to amounts paid in

  
 - 13 -

 
settlement of any such claim, loss, damage, liability or action if settlement is effected without the consent of the Company (which consent shall not unreasonably be withheld); and provided
further, that the Company will not be liable in any such case to the extent that any such claim, loss, damage, liability or expense arises out of or is based upon any untrue statement or omission based upon written information furnished to the
Company by such Holder, underwriter, or controlling person and stated to be for use in connection with the offering of securities of the Company. 
 3.6.2. Holder’s Indemnification of Company. To the extent permitted by law, each Holder will, if Registrable Securities held by such Holder are included in the securities as to which such
Registration, qualification or compliance is being effected pursuant to this Agreement, indemnify the Company, each of its directors and officers who has signed the registration statement, each underwriter, if any, of the Company’s securities
covered by such a Registration Statement, each person who controls the Company or such underwriter within the meaning of the Securities Act, and each other such Holder, each of its officers, directors and constituent partners, members, managers and
each person controlling such other Holder, against all claims, losses, damages and liabilities (or actions in respect thereof) arising out of or based upon any untrue statement (or alleged untrue statement) of a material fact contained in any such
Registration Statement, prospectus, offering circular or other document, or any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, or any
violation by such Holder of any rule or regulation promulgated under the Securities Act or Exchange Act or state or federal law applicable to such Holder and relating to action or inaction required of such Holder in connection with any such
Registration, qualification or compliance; and will reimburse the Company, such Holders, such directors, officers, partners, persons, underwriters or control persons for any legal and any other expenses reasonably incurred in connection with
investigating or defending any such claim, loss, damage, liability or action, in each case to the extent, but only to the extent, that such untrue statement (or alleged untrue statement) or omission (or alleged omission) is made in such Registration
Statement, prospectus, offering circular or other document in reliance upon and in conformity with written information furnished to the Company, and duly executed, by such Holder and stated to be specifically for use in connection with the offering
of securities of the Company; provided, however, that the indemnity contained in this Section 3.6.2 shall not apply to amounts paid in settlement of any such claim, loss, damage, liability or action if settlement is effected without the
consent of such Holder (which consent shall not unreasonably be withheld); and provided further, that each Holder’s liability under this Section 3.6.2 shall be several, and not joint with other Holders, and shall not exceed such
Holder’s net proceeds from the offering of securities made in connection with such Registration. 
 3.6.3.
Indemnification Procedure. Promptly after receipt by an indemnified party under this Section 3.6 of notice of the commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against an
indemnifying party under this Section 3.6, notify the indemnifying party in writing of the commencement thereof and generally summarize such action. The indemnifying party shall have the right to participate in and to assume the defense of such
claim; provided, however, that the indemnifying party shall be entitled to select counsel for the defense of such claim with the approval of any parties entitled to indemnification, which approval shall not be unreasonably withheld;
provided further, however, that if either party reasonably determines that there may be a conflict between the position of the indemnifying party and the indemnified party in conducting the defense of such action, suit or proceeding by reason
of recognized claims for indemnity under this Section 3.6, then counsel for such party shall be entitled to conduct the defense to the extent reasonably determined by such counsel to be necessary to protect the interest of such party. The
failure to notify an indemnifying party promptly of the commencement of any such action, if prejudicial to the ability of the indemnifying party to defend such action, shall relieve such indemnifying party, to the extent so prejudiced, of any
liability to the indemnified party under this Section 3.6, but the omission so to notify the indemnifying party will not relieve such party of any liability that such party may have to any indemnified party otherwise other than under this
Section 3.6. 

  
 - 14 -

 3.6.4. Contribution. If the indemnification provided for in this Section 3.6 is
held by a court of competent jurisdiction to be unavailable to an indemnified party with respect to any loss, liability, claim, damage or expense referred to therein, then the indemnifying party, in lieu of indemnifying such indemnified party
hereunder, shall contribute to the amount paid or payable by such indemnified party as a result of such loss, liability, claim, damage or expense in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one
hand and of the indemnified party on the other in connection with the statements or omissions that resulted in such loss, liability, claim, damage or expense as well as any other relevant equitable considerations; provided that, in no event
shall any contribution by a Holder under this Subsection 3.6 exceed the net proceeds from the offering received by such Holder. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among
other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent,
knowledge, access to information and opportunity to correct or prevent such statement or omission. 
 3.6.5. Underwriting
Agreement. Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the
foregoing provisions, the provisions in the underwriting agreement shall control. 
 3.6.6. Survival. The obligations of
the Company and Holders under this Section 3.6 shall survive the completion of any offering of Registrable Securities in a registration statement under this Section 3, and otherwise. No indemnifying party, in defense of any claim of
litigation set forth under this Section 3.6, shall, except with the consent of each indemnified party, consent to entry of any judgment or enter into any settlement that does not include as an unconditional term thereof the giving by the
claimant or plaintiff to such indemnified party of a release from all liability in respect to such claim or litigation. 
 3.7
Limitations on Registration Rights Granted to Other Securities. From and after the date of this Agreement, the Company shall not enter into any other agreement with any holder or prospective holder of any securities of the Company providing
for the granting to such holder of any information or Registration rights, except that, with the consent of the Holders of at least sixty-six and two-thirds percent (66 2/3%) of the Registrable Securities then outstanding, additional holders may be
added as parties to this Agreement with regard to any or all securities of the Company held by them. Any such additional parties shall execute a counterpart of this Agreement, and upon execution by such additional parties and by the Company, shall
be considered an Investor for all purposes of this Agreement. The additional parties and the additional Registrable Securities shall be identified in an amendment to Schedule A hereto. 

3.8 Transfer of Rights. The rights to information under Section 2 and the right to cause the Company to Register securities
granted by the Company to the Investors under Sections 3.1 and 3.2 may be assigned by any Holder to a transferee or assignee of any Convertible Securities or Registrable Securities not sold to the public acquiring at least One Hundred Twenty-Five
Thousand (125,000) shares of such Holder’s Registrable Securities (equitably adjusted for all stock splits, subdivisions, stock dividends, combinations and the like with respect to such shares); provided, however, that (i) the
Company must receive written notice prior to the time of said transfer, stating the name and address of said transferee or assignee and identifying the securities with respect to which such rights are being assigned, and (ii) with respect to
the rights to information and inspection under Section 2, the transferee or assignee of such rights must not be a person deemed by the Board, in its best judgment, to be a competitor or potential competitor of the Company. Notwithstanding the
limitation set forth in the foregoing sentence respecting the minimum number of shares which must be transferred, (a) any Holder which is a partnership may transfer such Holder’s rights to such Holder’s constituent partners, retired
partners (including spouses, ancestors, lineal descendants and siblings of such partners or spouses who 

  
 - 15 -

 
acquire Convertible Securities or Registrable Securities by gift, will or intestate succession), (b) any Holder which is a limited liability company may transfer such Holder’s rights to
such Holder’s constituent members or retired members (including spouses, ancestors, lineal descendants and siblings of such members or spouses who acquire Convertible Securities or Registrable Securities by gift, will or intestate succession),
(c) any Holder which is a natural person may transfer such Holder’s rights to any immediate family member or to any trust created for the benefit of such Holder or his or her immediate family members, (d) any Holder that is a
partnership or limited liability company may transfer such Holder’s rights to an Affiliate, subject in each case to such transferee’s agreeing to be bound by the rights and restrictions of this Agreement, and (e) any Holder may
transfer such Holder’s rights to any other Holder who has the right to cause the Company to Register securities granted by the Company to the Investors under Sections 3.1 and 3.2. The rights under Sections 4 and 5 may be assigned by an Investor
only as provided in such Sections. 
 3.9 Market Stand-off. If requested in writing by the underwriters for the initial
public offering of the Company’s Common Stock, each holder of Registrable Securities who is a party to this Agreement shall agree not to sell publicly any shares of Registrable Securities or any other securities of the Company (other than
shares of Registrable Securities or other securities of the Company being registered in such offering), without the consent of such underwriters, for a period of not more than one hundred eighty (180 days) following the effective date of the
registration statement relating to such offering; provided, however, that the Company shall use commercially reasonable efforts to convince such managing underwriters to allow for alternative means of liquidity for the holders if, in the
opinion of such managing underwriters, such liquidity can be provided without an adverse impact on such initial public offering; and, provided, further, however, that all persons entitled to registration rights with respect to shares of
Common Stock who are not parties to this Agreement, all other persons selling shares of Common Stock in such offering and all executive officers and directors of the Company and holders of at least one percent (1%) of the Company’s voting
securities shall also have agreed not to sell publicly their Common Stock under the circumstances and pursuant to the terms set forth in this section. Each Holder agrees to execute and deliver such other agreements as may be reasonably requested by
the Company, or the Company’s underwriters, which are consistent with the foregoing, or which are reasonably necessary to give further effect thereto. 
 3.10 Sale of Convertible Securities to Underwriter. Notwithstanding any provision in this Agreement to the contrary, in lieu of converting any Convertible Securities prior to the filing of any
Registration Statement filed pursuant to this Agreement, the holder of such Convertible Securities may sell such Convertible Securities to the underwriters of the offering being Registered upon the undertaking of such underwriters to convert the
Convertible Securities on or prior to the closing date of the offering. If and when the Convertible Securities are converted in accordance with their applicable terms and conditions, the Company agrees to cause the Common Stock issuable on the
conversion of the Convertible Securities to be issued within such time period as will permit the underwriters to make and complete the distribution contemplated by the underwriting. 

3.11 Rule 144 Requirements. Immediately after the date on which a Registration Statement filed by the Company under the Securities
Act becomes effective, the Company shall undertake to make publicly available, and available to the Holders of Registrable Securities, such information as is necessary to enable the holders of Registrable Securities to make sales of Registrable
Securities pursuant to Rule 144 of the Commission under the Securities Act. The Company shall furnish to any holder of Registrable Securities, upon request, a written statement executed by the Company as to the steps it has taken to comply with the
current public information requirements of Rule 144. 
 3.12 Termination of Company Agreements. The Registration
rights set forth in Sections 3.1 and 3.2 shall terminate seven (7) years after the effective date of the Company’s Registration Statement 

  
 - 16 -

 
filed in connection with the Company’s first Qualified Public Offering or, as to any Holder, at any time following the effective date of the Company’s first Qualified Public Offering,
when such Holder is entitled to sell all of such Investor’s Registrable Securities pursuant to Rule 144 (including Rule 144(k)) of the Commission under the Securities Act. 

 

	SECTION 4.	RIGHT OF FIRST REFUSAL 

4.1 Right of First Refusal. The Company hereby grants to each Investor the right of first refusal to purchase such Investor’s
pro rata share of New Securities (as defined in Section 4.2) which the Company may from time to time propose to sell and issue (the “Right of First Refusal”); provided that the Investors may waive the Right of First
Refusal as to all Investors with the consent of the Investors holding at least sixty-six and two-thirds percent (66 2/3%) of the Convertible Securities then outstanding. For purposes of the Right of First Refusal an Investor’s pro rata share
(the “ROFR Pro Rata Share”) shall be equal to that number or amount of New Securities to be sold multiplied by a fraction, the numerator of which shall be the number of shares of Common Stock owned by such Investors (including
shares of Common Stock issuable upon the conversion of all Convertible Securities and the exercise of all options and warrants owned by such Investor) and the denominator of which shall be the total number of shares of the Company’s Common
Stock deemed to be outstanding assuming the conversion of all outstanding convertible securities. Notwithstanding the foregoing, any Investor (the “Subscribing Investor”) may, at the time it accepts the Company’s offer,
subscribe to purchase any or all of the securities offered (“Oversubscription Securities”) which may be available as a result of the rejection, or partial rejection, of the offer by other Investors. All such Oversubscription
Securities shall be allocated on a pro rata basis among those Investors subscribing to purchase them. For purposes of the Oversubscription Securities a Subscribing Investor’s pro rata share (the “Oversubscription Pro Rata
Share”) shall be equal to that number or amount of Oversubscription Securities to be sold multiplied by a fraction, the numerator of which shall be the number of shares of Common Stock owned by such Subscribing Investor (including shares of
Common Stock issuable upon the conversion of all Convertible Securities and the exercise of all options and warrants owned by such Investor) and the denominator of which shall be the total number of shares of the Common Stock owned in aggregate by
all of the Subscribing Investors (including shares of Common Stock issuable upon the conversion of all Convertible Securities and the exercise of all options and warrants owned by such Investors). Notwithstanding the foregoing, the Company shall not
be required to offer or sell such New Securities to any Investor who would cause the Company to be in violation of applicable federal securities laws by virtue of such offer or sale. The Right of First Refusal shall be subject to the following
provisions: 
 4.2 Definition of New Securities. “New Securities” shall mean any shares of Common Stock
or Preferred Stock of the Company, whether now authorized or not, and rights, options, or warrants to purchase such shares of Common Stock or Preferred Stock, and all other securities having equity features, such as convertible notes or notes issued
in conjunction with options or warrants; provided that “New Securities” shall not include: 
 (a)
securities issued upon the conversion of any shares of the Series A Preferred Stock; 
 (b) securities issued to the
Company’s employees or officers or directors or outside consultants or contractors pursuant to a plan, agreement or arrangement duly approved by the Board; 
 (c) securities issued pursuant to a Qualified Public Offering; 
 (d) securities
issued or issuable pursuant to the exercise or conversion of options, warrants or convertible securities (including, without limitation, the Convertible Promissory Notes) outstanding as of the date hereof; 

  
 - 17 -

 (e) securities issued to effect any stock split, stock dividend or recapitalization of the
Company; 
 (f) securities issued in connection with any borrowings, direct or indirect, from financial institutions or other
persons by the Company, provided that such issuance is pursuant to an agreement or arrangement duly approved by the Board; 
 (g) securities issued in connection with the Company obtaining lease financing, whether issued to a lessor, guarantor or other person, provided that such issuance is pursuant to an agreement or
arrangement duly approved by the Board; 
 (h) securities issued in connection with the acquisition of all or a substantial
portion of the assets or the business of another entity by the Company provided that such issuance is pursuant to an agreement or arrangement duly approved by the Board; 

(i) securities issued in connection with a corporate partnering transaction, strategic alliance, technology acquisition or transfer, or
similar transaction, provided such issuance is pursuant to an agreement or arrangement duly approved by the Board; and 

(j) any right, option or warrant to acquire any security convertible into the securities excluded from the definition of New Securities
pursuant to subsections (a) through (i) above. 
 4.3 Notices. In the event the Company proposes to undertake
an issuance of New Securities, it shall give each Investor written notice (the “Notice”) of its intention, describing the type of New Securities, the price, and the principal terms upon which the Company proposes to issue the same.
Each Investor shall have twenty (20) days from the delivery of the Notice to agree to purchase up to the Investor’s ROFR Pro Rata Share plus any Oversubscription Pro Rata Share for the price and upon the terms specified in the Notice by
giving written notice to the Company and stating therein the quantity of New Securities and Oversubscription Securities to be purchased. 
 4.4 Failure to Exercise Right. In the event an Investor does not elect to purchase all of such Investor’s ROFR Pro Rata Share of the New Securities pursuant to Section 4.1 and such New
Securities are not purchased by other Investors, the Company shall have sixty (60) days after the last date on which any Investor’s right to purchase lapsed to sell or enter into an agreement (pursuant to which the sale of New Securities
covered thereby shall be closed, if at all, within twenty (20) days from the date of said agreement) to sell the New Securities respecting which such Investor’s option was not exercised, at or above the price and upon terms not materially
more favorable to the purchasers of such securities than the terms specified in the initial Notice given in connection with such sale. In the event the Company has not sold the New Securities within said 60-day period (or sold and issued New
Securities in accordance with the foregoing within twenty (20) days from the date of said agreement), the Company shall not thereafter issue or sell any New Securities without first offering such New Securities to the Investors in the manner
provided in this Section 4. 
 4.5 Rights of Affiliated Investors. For the purposes of this Section 4,
Investors who are Affiliates of one or more other Investors shall, at the election of an Investor and one or more such Affiliates, be treated as a group (an “Investor Group”). Members of an Investor Group shall have the right to
reallocate the rights granted by this Section 4 among themselves as they determine. 
 4.6 Assignment. The Right of
First Refusal set forth in this Section 4 may not be assigned or transferred, except that each Investor shall have the right to assign its right to purchase securities under this Section 4 to any Affiliate of such Investor, partner,
member, retired partner or retired member; provided such Affiliate agrees in writing with the Company and the Investors, prior to and as a condition precedent to such transfer, to be bound by all the provisions of Sections 3.9, 5 and 6 of
this Agreement. 

  
 - 18 -

 4.7 Termination. The Right of First Refusal granted under this Section 4 shall
not apply to, and shall terminate on and be of no further force or effect upon the earlier of (a) the closing of the first Qualified Public Offering and (b) the date of the closing of a sale, lease, or other disposition of all or
substantially all of the Company’s assets or the Company’s merger into or consolidation with any other corporation or other entity, or any other corporate reorganization, in which the holders of the Company’s outstanding voting stock
immediately prior to such transaction own, immediately after such transaction, securities representing less than fifty percent (50%) of the voting power of the corporation or other entity surviving such transaction, provided that this
Section 4.7 shall not apply to a merger effected exclusively for the purpose of changing the domicile of the Company or a sale of shares by the Company for primarily equity financing purposes. 

 

	SECTION 5.	TRANSFERS OF SECURITIES BY INVESTORS. 

 5.1 Notices. If any Investor (the “Transferor”) proposes to sell, assign, hypothecate or otherwise transfer (a “Transfer”) any securities of the Company owned by
such Investor from and after the date of this Agreement, other than pursuant to the provisions of Section 5.6 of this Agreement, the Transferor shall first give each of the other Investors the right to purchase such securities by delivering to
them a written offer which shall state the price and other terms and conditions of the proposed Transfer. If the Transferor proposes to Transfer the securities for consideration other than solely cash and/or promissory notes, the offer to the
Investors shall, to the extent of such consideration, permit each Investor to pay in lieu thereof, cash equal to the fair market value of such consideration, and the offer shall state the estimate of such fair market value as determined by the
Board. The Transferor shall fix the period of the offer which shall be a minimum of thirty (30) days or such longer period as is necessary to determine the fair market value of the consideration referred to in the preceding sentence.

 5.2 Acceptance of Offer. An Investor may accept an offer (“Purchasing Investor”) only by giving
written notice to the Transferor before the offer expires that such Purchasing Investor has accepted the offer to purchase some or all of the securities offered (the “Accepted Securities”); provided, however, that the maximum
number or amount of securities a Purchasing Investor shall be entitled to purchase shall be equal to that number or amount of securities to be transferred multiplied by a fraction, the numerator of which shall be the number of shares of Common Stock
owned by such Purchasing Investor (including shares of Common Stock issuable upon the conversion of all Convertible Securities and the exercise of all options and warrants owned by such Investor) and the denominator of which shall be the aggregate
number of shares of Common Stock held by all Investors (including shares of Common Stock issuable upon the conversion of all Convertible Securities and the exercise of all options and warrants owned by all Investors), excluding the Transferor’s
shares of Common Stock. Notwithstanding the foregoing, any Purchasing Investor may, at the time it accepts the offer, subscribe to purchase any or all securities offered which may be available as a result of the rejection, or partial rejection, of
the offer by other Investors, which securities shall be allocated on a pro rata basis among those Purchasing Investors subscribing to purchase them. 
 5.3 Allocation of Securities and Payment. Promptly following the expiration of an offer, the Transferor shall allocate the securities subscribed for among the Purchasing Investors accepting or
partially accepting the offer, pro rata, based upon their respective holdings as aforesaid, and shall by written notice (the “Acceptance Notice”) advise all Purchasing Investors of the number or amount of securities allocated to
each of the Purchasing Investors. Within ten (10) days following receipt of the Acceptance Notice, each of the Purchasing Investors shall deliver to the Transferor payment in full for the Accepted Shares purchased by it against delivery by the
Transferor to each Purchasing Investor of a certificate or certificates evidencing the Accepted Securities purchased by it. 

  
 - 19 -

 5.4 Failure to Exercise. To the extent an offer pursuant to Section 5.1 is not
accepted by the other Investors, the Transferor may, for a period of ninety (90) days thereafter, transfer the unaccepted securities, or any of them, at or above the price, and upon the other terms and conditions specified in such offer, to any
Person or Persons; provided that such Person or Persons agrees in writing with the Company and the Investors, prior to and as a condition precedent to such Transfer, to be bound by all of the provisions of Sections 3.9, 5 and 6 of this
Agreement and the provisions of the Voting Agreement. 
 5.5 Assignment. The right of first refusal set forth in this
Section 5 may not be assigned or transferred, except that each Investor shall have the right to assign its rights to purchase such securities under this Section 5 to any Affiliate of such Investor; provided such Affiliate agrees in
writing with the Company and the Investors, prior to and as a condition precedent to such assignment, to be bound by all of the provisions of Sections 3.9, 5 and 6 of this Agreement and the provisions of the Voting Agreement. 

5.6 Permitted Transfers. 
 (a) Notwithstanding anything to the contrary contained herein, any Investor which is a partnership may transfer, without first offering any securities of the Company to the other Investors, all or any of
its securities to any of its Affiliates or successor funds or to a partner or retired partner or member or retired member of such partnership or limited liability company, as the case may be, or to one or more direct or indirect partners, members or
other equity holders of any such Affiliates, successor funds, partners or retired partners, members or retired members, or to the estate of any of the foregoing or transfer by will or intestate succession to the spouse or to the siblings, lineal
descendants or ancestors of any of the foregoing or the spouse of any of the foregoing; provided such transferee agrees in writing with the Company and the Investors, prior to and as a condition precedent to such Transfer, to be bound by all
of the provisions of Sections 3.9, 5 and 6 of this Agreement and the provisions of the Voting Agreement. 
 (b) Notwithstanding
anything to the contrary contained herein, any Investor which is a corporation may Transfer, without first offering any securities of the Company to the other Investors, all or any of its securities to any of its Affiliates; provided such
Affiliate agrees in writing with the Company and the Investors, prior to and as a condition precedent to such Transfer, to be bound by all of the provisions of Sections 3.9, 5 and 6 of this Agreement and the provisions of the Voting Agreement.

 (c) Notwithstanding anything to the contrary contained herein, any Investor who is an individual may Transfer, without first
offering any securities of the Company to the other Investors, all or any of his or her securities to his or her spouse or their spouse’s siblings, lineal descendants or ancestors, nieces or nephews, or any entity that is an Affiliate of such
Investor; provided such transferee agrees in writing with the Company and the Investors, prior to and as a condition precedent to such Transfer, to be bound by all of the provisions of Sections 3.9, 5 and 6 of this Agreement and the
provisions of the Voting Agreement. 
 (d) Notwithstanding the foregoing, any Investor may Transfer, without first offering any
securities of the Company to the other Investors, all or any of its securities to one or more other Investors hereunder. 
 5.7
Termination. The right of first refusal granted under this Section 5 shall expire upon the closing of the first Qualified Public Offering and shall not be applicable to any shares sold pursuant thereto. 

  
 - 20 -

	SECTION 6.	MISCELLANEOUS. 

 6.1
Entire Agreement; Successors and Assigns. This Agreement constitutes the entire contract between the Company and the Investors relative to the subject matter hereof. Any previous agreement between the Company, the Investors and the Holders
concerning Registration rights and the other matters set forth herein, is superseded by this Agreement. Subject to the exceptions specifically set forth in this Agreement, the terms and conditions of this Agreement shall inure to the benefit of and
be binding upon the respective executors, administrators, heirs, successors and assigns of the parties. 
 6.2 Aggregation of
Stock. All Convertible Securities and Registrable Securities held or acquired by affiliated entities or persons shall be aggregate together for the purpose of determining the availability of any rights under this Agreement. 

6.3 Governing Law. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF CALIFORNIA
APPLICABLE TO CONTRACTS ENTERED INTO AND WHOLLY TO BE PERFORMED WITHIN THE STATE OF CALIFORNIA BY CALIFORNIA RESIDENTS. 
 6.4
Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 

6.5 Headings. The headings of the Sections of this Agreement are for convenience and shall not by themselves determine the
interpretation of this Agreement. 
 6.6 Notices. Any notice required or permitted hereunder shall be given in writing
and shall be conclusively deemed effectively given upon personal delivery, or five (5) days after deposit in the United States mail, by registered or certified mail (or airmail, if notice shall be sent outside the United States), postage
prepaid, or two (2) days after delivery to a nationally known air courier company, addressed (i) if to the Company, to the Company’s address as set forth below the Company’s name on the signature page of this Agreement and
(ii) if to an Investor, to such Investor’s address as set forth on the signature page of this Agreement, or at such other address as the Company or such Investor may designate by ten (10) days, advance written notice to the other
parties hereto. Any notice sent outside the United States shall also be telexed or telecopied. 
 6.7 Amendment of Agreement;
Waivers. Subject to Section 3.7 and Section 4.1, any provision of this Agreement may be amended or waived by a written instrument signed by the Company and by Persons holding at least sixty-six and two-thirds percent (66 2/3%) of,
prior to the closing of the first Qualified Public Offering, the Series A Preferred Stock, and after such closing, the Registrable Securities. Any amendment or waiver effected in accordance with Section 3.7, Section 4.1 or this
Section 6.7 shall be binding upon the Company and all Holders and each of their respective successors and assigns. 
 6.8
Additional Investors. Notwithstanding anything to the contrary contained herein, if the Company shall issue additional shares of its Series A Preferred Stock pursuant to the Purchase Agreement, any purchaser of such shares of Series A
Preferred Stock shall become a party to this Agreement by executing and delivering an additional counterpart signature page to this Agreement and shall be deemed an “Investor” hereunder and Schedule A shall be amended accordingly.

 [Remainder of Page Intentionally Left Blank] 

  
 - 21 -

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first
above written. 
  

			
	COMPANY:
	
	EVOKE PHARMA, INC.
		
	By:	 	 /s/ DAVID A. GONYER

		 	David A. Gonyer
		 	President

  

			
	Address:	 	12636 High Bluff Drive, Suite 400
		 	San Diego, California 92130

  

EVOKE PHARMA, INC. 
 INVESTOR RIGHTS AGREEMENT 

COUNTERPART SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year
first above written. 
  

							
	INVESTORS:
	
	GARNER INVESTMENTS, L.L.C.
		
	By:	 	 /s/ CAM L. GARNER

		 	Name:	 	Cam L. Garner
		 	Title:	 	President

 

					
		 	Address:	 	 P.O. Box 675866
 5949 Greenview
Court

		 		 	Rancho Santa Fe, CA 92067

  

EVOKE PHARMA, INC. 
 INVESTOR RIGHTS AGREEMENT 

COUNTERPART SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year
first above written. 
  

							
	INVESTORS:
	
	WINDAMERE III, LLC
		
	By:	 	 /s/ SCOTT L. GLENN

		 	Name:	 	Scott L. Glenn
		 	Title:	 	Managing Member

 

					
		 	Address:	 	6402 Cardeno Drive
		 		 	La Jolla, CA 92037
		 		 	Fax No.: (858) 456-2295

  

EVOKE PHARMA, INC. 
 INVESTOR RIGHTS AGREEMENT 

COUNTERPART SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year
first above written. 
  

							
	INVESTORS:
	
	HALE BIOPHARMA VENTURES, LLC
		
	By:	 	 /s/ DAVID F. HALE

		 	Name:	 	David F. Hale
		 	Title:	 	Chief Executive Officer

 

							
		 	Address:	 	1042-B El Camino Real, Suite 430
		 		 	Encinitas, CA 92024-1322

  

EVOKE PHARMA, INC. 
 INVESTOR RIGHTS AGREEMENT 

COUNTERPART SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year
first above written. 
  

					
	INVESTORS:
	
	DOMAIN PARTNERS VII, L.P.
		
	By:	 	One Palmer Square Associates VII, L.L.C.
	Its:	 	General Partner
		
	By:	 	 /s/ KATHLEEN K. SCHOEMAKER

		 	Name:	 	Kathleen K. Schoemaker
		 	Title:	 	Managing Member

  

					
		 	Address:	 	One Palmer Square, Suite 515
		 		 	Princeton, NJ 08542

 

					
	DP VII ASSOCIATES, L.P.
		
	By:	 	One Palmer Square Associates VII, L.L.C.
	Its:	 	General Partner
		
	By:	 	 /s/ KATHLEEN K. SCHOEMAKER

		 	Name:	 	Kathleen K. Schoemaker
		 	Title:	 	Managing Member

  

					
		 	Address:	 	One Palmer Square, Suite 515
		 		 	Princeton, NJ 08542

  

EVOKE PHARMA, INC. 
 INVESTOR RIGHTS AGREEMENT 

COUNTERPART SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year
first above written. 
  

			
	INVESTORS:
	
	LATTERELL VENTURE PARTNERS III, L.P.
		
	By:	 	Latterell Capital Management III, L.L.C.
	Its:	 	General Partner
		
	By:	 	 /s/ PATRICK F. LATTERELL

	Name:	 	Patrick F. Latterell
	Its:	 	Managing Member
	
	LVP III ASSOCIATES, L.P.
		
	By:	 	Latterell Capital Management III, L.L.C.
	Its:	 	General Partner
		
	By:	 	 /s/ PATRICK F. LATTERELL

	Name:	 	Patrick F. Latterell
	Its:	 	Managing Member
	
	LVP III PARTNERS, L.P.
		
	By:	 	Latterell Capital Management III, L.L.C.
	Its:	 	General Partner
		
	By:	 	 /s/ PATRICK F. LATTERELL

	Name:	 	Patrick F. Latterell
	Its:	 	Managing Member

  

			
	Address:	 	1 Embarcadero Center
		 	Suite 4050
		 	San Francisco, CA 94111

  

EVOKE PHARMA, INC. 
 INVESTOR RIGHTS AGREEMENT 

COUNTERPART SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as
of the 16th day of June 2010. 

 

			
	INVESTORS:
	
	CAM GALLAGHER
	
	 /s/ CAM GALLAGHER

		
	Address:	 	3888 Quarter Mile Drive
		 	San Diego, CA 92130

  

EVOKE PHARMA, INC. 
 INVESTOR RIGHTS AGREEMENT 

COUNTERPART SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as
of the 16th day of June 2010. 

 

					
	INVESTORS:
	
	STEPHEN F. GALLAGHER, TRUSTEE WITH FIRST NATIONAL BANK, N.A., AS SUCCESSOR TRUSTEE U/A DATED MARCH 21, 2005 AS MAY BE AMENDED
		
	By:	 	 /s/ STEPHEN F. GALLAGHER, TRUSTEE

		 	Name:	 	Stephen F. Gallagher
		 	Title:	 	Trustee

  

					
	Address:	 	4101 Beachside One Drive
		 	Destin, FL 32550

  

EVOKE PHARMA, INC. 
 INVESTOR RIGHTS AGREEMENT 

COUNTERPART SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as
of the 16th day of June 2010. 

 

			
	INVESTORS:
	
	MICHAEL J. POLLOCK
	
	 /s/ MICHAEL J. POLLOCK

		
	Address:	 	3721 Roosevelt Blvd.
		 	Middletown, OH 45044

  

EVOKE PHARMA, INC. 
 INVESTOR RIGHTS AGREEMENT 

COUNTERPART SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as
of the 16th day of June 2010. 

 

			
	INVESTORS:
	
	ADAM COHEN
	
	 /s/ ADAM COHEN

		
	Address:	 	One McKittrick Court
		 	Old Tappan, NJ 07675

  

EVOKE PHARMA, INC. 
 INVESTOR RIGHTS AGREEMENT 

COUNTERPART SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as
of the 16th day of June 2010. 

 

			
	INVESTORS:
	
	LARRY TIFFANY
	
	 /s/ LARRY TIFFANY

		
	Address:	 	21504 Quick Fox Lane
		 	Gaithersburg, MD 20882

  

EVOKE PHARMA, INC. 
 INVESTOR RIGHTS AGREEMENT 

COUNTERPART SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as
of the 16th day of June 2010. 

 

			
	INVESTORS:
	
	KEN WORMSER
	
	 /s/ KEN WORMSER

		
	Address:	 	31 Boset Rd.
		 	Demerst, NJ 07627

  

EVOKE PHARMA, INC. 
 INVESTOR RIGHTS AGREEMENT 

COUNTERPART SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as
of the 16th day of June 2010. 

 

			
	INVESTORS:
	
	DAVID PARKS
	
	 /s/ DAVID PARKS

		
	Address:	 	64 East 86th Street, #12C
		 	New York, NY 10028

  

EVOKE PHARMA, INC. 
 INVESTOR RIGHTS AGREEMENT 

COUNTERPART SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as
of the 16th day of June 2010. 

 

			
	INVESTORS:
	
	ROEY EYAL
	
	 /s/ ROEY EYAL

		
	Address:	 	120 w. 21st St., # 1502
		 	New York, NY 10011

  

EVOKE PHARMA, INC. 
 INVESTOR RIGHTS AGREEMENT 

COUNTERPART SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as
of the 16th day of June 2010. 

 

					
	INVESTORS:
	
	NERVEDA, INC.
		
	By:	 	 /s/ CAM GALLAGHER

		 	Name:	 	Cam Gallagher
		 	Title:	 	President and Chief Executive Officer

 

					
	Address:	 	3888 Quarter Mile Drive
		 	San Diego, CA 92130

  

EVOKE PHARMA, INC. 
 INVESTOR RIGHTS AGREEMENT 

COUNTERPART SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as
of the 16th day of June 2010. 

 

					
	INVESTORS:
	
	VP COMPANY INVESTMENTS 2008, LLC
		
	By:	 	 /s/ ALAN C. MENDELSON

		 	Name:	 	Alan C. Mendelson
		 	Title:	 	Managing Member

  

					
	Address:	 	555 W. Fifth Street, Suite, 800
		 	Los Angeles, CA 90013-1010
		 	Attn.: Alfred Harutunian

  

EVOKE PHARMA, INC. 
 INVESTOR RIGHTS AGREEMENT 

COUNTERPART SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as
of the 16th day of June 2010. 

 

			
	INVESTORS:
	
	SCOTT N. WOLFE
	
	 /s/ SCOTT N. WOLFE

		
	Address:	 	c/o Latham & Watkins LLP
		 	12636 High Bluff Drive, Suite 400
		 	San Diego, CA 92130

  

EVOKE PHARMA, INC. 
 INVESTOR RIGHTS AGREEMENT 

COUNTERPART SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as
of the 16th day of June 2010. 

 

					
	INVESTORS:
	
	FAYE HUNTER RUSSELL TRUST U/T/D 7/11/88
		
	By:	 	 /s/ FAYE H. RUSSELL

		 	Name:	 	Faye H. Russell
		 	Title:	 	Trustee

  

					
	Address:	 	c/o Latham & Watkins LLP
		 	12636 High Bluff Drive, Suite 400
		 	San Diego, CA 92130

  

EVOKE PHARMA, INC. 
 INVESTOR RIGHTS AGREEMENT 

COUNTERPART SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as
of the 16th day of June 2010. 

 

			
	INVESTORS:
	
	CHESTON J. LARSON
	
	 /s/ CHESTON J. LARSON

		
	Address:	 	c/o Latham & Watkins LLP
		 	12636 High Bluff Drive, Suite 400
		 	San Diego, CA 92130

  

EVOKE PHARMA, INC. 
 INVESTOR RIGHTS AGREEMENT 

COUNTERPART SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as
of the 16th day of June 2010. 

 

			
	INVESTORS:
	
	MATTHEW T. BUSH
	
	 /s/ MATTHEW T. BUSH

		
	Address:	 	c/o Latham & Watkins LLP
		 	12636 High Bluff Drive, Suite 400
		 	San Diego, CA 92130

  

EVOKE PHARMA, INC. 
 INVESTOR RIGHTS AGREEMENT 

COUNTERPART SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as
of the 16th day of June 2010. 

 

					
	INVESTORS:
	
	WS INVESTMENT COMPANY, LLC (2010A)
		
	By:	 	 /s/ [ILLEGIBLE]

		 	Name:	 	
		 	Title:	 	

  

			
	Address:	 	60 Page Mill Road
		 	Palo Alto, CA 94304-1050

  

EVOKE PHARMA, INC. 
 INVESTOR RIGHTS AGREEMENT 

COUNTERPART SIGNATURE PAGE 

 SCHEDULE A 

June 1, 2007 
 INVESTORS 
 Investors 

GARNER INVESTMENTS, L.L.C. 
 WINDAMERE III, LLC

 HALE BIOPHARMA VENTURES, LLC 

DOMAIN PARTNERS VII, L.P. 
 DP VII ASSOCIATES,
L.P. 
 LATTERELL VENTURE PARTNERS III, L.P. 
 LVP III ASSOCIATES, L.P. 
 LVP III PARTNERS, L.P 

Additional Investors as of June 16, 2010 
 Investors 
 CAM GALLAGHER 
 STEPHEN F. GALLAGHER, TRUSTEE WITH FIRST 
 NATIONAL BANK, N.A., AS SUCCESSOR TRUSTEE 

U/A DATED MARCH 21, 2005 AS MAY BE AMENDED 

MICHAEL J. POLLOCK 
 ADAM COHEN 

LARRY TIFFANY 
 KEN WORMSER 

DAVID PARKS 
 ROEY EYAL 

NERVEDA, INC. 
 VP COMPANY INVESTMENTS 2008,
LLC 
 SCOTT N. WOLFE 
 FAYE HUNTER
RUSSELL TRUST U/T/D 7/11/88 
 CHESTON J. LARSON 
 MATTHEW T. BUSH 
 WS INVESTMENT COMPANY, LLC (2010A)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00217-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00217-of-00352.parquet"}]]